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MCP1/CCL2    Monocyte chemoattractant protein 1 
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MEF2c                Myocyte-specific enhancer factor 2C 
MHCII                Major histocompatibility complex class II  
MMP9                Matrix metalloproteinase  
MOSE                Mouse ovarian surface epithelial 
MPS     Mononuclear phagocyte system 
NK                 Natural Killer 
PBS                 Phosphate buffered saline 
PI3K     Phosphatidylinositide 3-kinases 
PKC     Protein kinase C 
PPARγ                Proliferator-activated receptor-γ 
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SOCS     Suppressor of cytokine signaling 
SPM     Small peritoneal macrophages 
STAT     Signal transducer and activator of transcription  
TAM     Tumor-associated macrophage 
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TGFβ     Tumor growth factor beta 
TLR4     Toll like receptor four 
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VEGFα                Vascular endothelial growth factor- A 
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Chapter I : Myeloid cells differentiation and 
activation 
 
 
 
The mononuclear phagocyte system  
 
 
The immune system comprises a variety of cell types and structures, which form a 
complex network where each component performs a specific function with the final goal 
of protecting the organism against pathogens and transformed cells. Classically, the 
immune system has been divided into innate and adaptive elements. The innate immune 
system is the first-line of defense that responds to pathogenic challenge and provides a 
robust and rapid response, within minutes of pathogen exposure, to generate a protective 
inflammatory response. Moreover, innate immunity plays a central role in activating the 
subsequent adaptive immune response. In turn, adaptive immunity refers to a group of 
specialized cells that have the capability to generate a memory immune response against 
pathogens once innate immune cells have presented them with specific antigens. The 
recognition of danger signals by immune cells triggers an inflammatory response that 
includes the secretion of cytokines and chemokines and the recruitment of phagocytic 
cells. The hematopoietic cells that integrate the adaptive immunity system include B and 
T lymphocytes while innate immune responses are mediated by macrophages, dendritic 
cells, mast cells, neutrophils, eosinophils, natural killer (NK) cells, and NK T cells. Most 
cell populations in the innate immune system arise from hematopoietic progenitors cells 
in the bone marrow that constitute the so-called mononuclear phagocyte system (MPS).  
 
 
Innate immune cells within the MPS are responsible for the maintenance of homeostatic 
surveillance, reaction to infection and injury as well as for the regenerative response after 
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the injury. Van Furth and colleagues initially proposed the concept of MPS in the 1970's 
with a basic and linear model (Van Furth and Cohn, 1968, Yona et al., 2013; Cassado et 
al., 2015). The MPS has been now expanded to include subpopulations regulated by 
specific growth and transcription factors as well as epigenetic modifications that result in 
subset-specific gene expression signatures, and distinct ontogenies, that include myeloid 
cells, however, some of these cells have an origin that is other than bone marrow 
hematopoietic stem cells (HSCs) (Davies and Taylor, 2015, Alvarez-Errico et al., 2015).  		
Macrophages are myeloid cells that play central roles in tissue homeostasis and 
pathophysiological responses like host defense against infections, tissue repair, and 
inflammation, through various scavenger, pattern recognition, and phagocytic receptors.  
These functions enable macrophages to initiate appropriate inflammatory programs upon 
perturbation of homeostasis. Conversely, deregulated macrophage activation could occur 
during inflammation and in a number of diseases, including cancer (Wynn et al., 2013; 
Franklin and Li, 2016).  
 
 
The central paradigm established by the MPS concept were twofold: first, that tissue-
resident macrophages in homeostasis are maintained through the continuous recruitment 
of blood monocytes produced by bone marrow HSCs and, second, that macrophages are 
fully differentiated cells that have lost their proliferative potential. This model occurs as a 
linear process wherein progenitor cells in the bone marrow generate circulating blood 
monocytes that upon arrival into tissues can differentiate into macrophages. It was based 
on the observation that blood leukocytes recruited into the inflamed peritoneum can 
differentiate into mature macrophages (Chow et al., 2011).   
 
 
However, macrophage populations do not necessarily share the same origin, arising 
either from embryonic progenitors, such as yolk sac macrophages and fetal monocytes or 
from adult blood monocytes. Yolk sac erythromyeloid progenitors (EMPs) have both 
erythroid and myeloid potential. EMP-derived hematopoiesis gives rise to erythrocytes, 
macrophages, monocytes, granulocytes and mast cells. Macrophages are found in the 
mouse yolk sac before the initiation of HSCs-derived hematopoiesis as early as 
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embryonic day 9 (E9), before the establishment of the circulatory system (Ginhoux and 
Jung, 2014). Two highly coordinated waves of hematopoiesis have been identified, 
referred to as "primitive" and "definitive."  
 
 
The first early “primitive” wave is c-Myb- and Notch1-independent and generates 
primitive macrophages without monocytic intermediates in the yolk sac. The second 
"definitive" wave begins when HSCs appear in the aorta gonadal mesonephros region at 
approximately day 10.5 of embryonic development (E10.5). This second wave is c-Myb- 
and Notch1-dependent, and these precursors are capable of maintaining blood circulating 
cells lifelong. EMPs embryonic precursors of yolk sac macrophages and fetal monocytes 
can be distinguished according to the anatomical site (extra-embryonic yolk sac versus 
intra-embryonic region), their differentiation potential and their dependence on 
transcription factors. Thus, tissue resident macrophages are thought to arise 
independently of blood monocytes, and also can originate by in situ self-renewal 
(Hashimoto et al., 2013).  
 
 
EMP-derived macrophages from these first non-hematopoietic precursors colonize all 
tissues during fetal development, where they specialize in their tissue of residence after 
birth and appear to persist throughout adult life by local proliferation through a process 
of self-renewal (Varol et al., 2015; Bertrand et al., 2010). Examples of these 
macrophages include microglia of the central nervous system and some Langerhans cells 
in the epidermis (Figure 1). These results have been obtained through parabiosis of 
congenic mice that confirmed that the homeostatic maintenance of these macrophages 
populations is largely independent of blood monocytes expressing the C-C chemokine 
receptor type 2 (CCR2). CCR2 is highly expressed in monocytes, which is the basis of 
hematopoiesis derived from HSC (Hashimoto et al., 2013; Yona et al., 2013).  
 
 
However, in some tissues, resident macrophages derive from circulating monocytes like 
intestinal macrophages of the colonic mucosa that are continually replenished from 
circulating monocytes. In other tissues like heart, epidermis, and peritoneal cavity, a 
smaller subset of monocyte-derived macrophages can be found in homeostatic 
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conditions, derived from the physiological recruitment of monocyte population. 
Nevertheless, in the context of inflammation, upon radiation or in ischemic tissues, the 
recruitment and differentiation of blood monocytes may be involved in the maintenance 
of tissue-resident macrophages population. Likewise, during aging, tissue-resident 
macrophages in the heart and lung are replenished from monocytes (Lavin et al., 2015; 
Hoeffel et al., 2015; Miró-Mur et al., 2016). Interestingly, other studies found that tissue 
macrophages were replaced by adult bone marrow–derived cells, not necessarily by 
monocytes. This indicates that adult bone marrow–derived cells can acquire phenotypic 
and functional features and exhibit a gene expression profile similar to the original tissue 
macrophage population, with the tissue environments ultimately dictating macrophages’ 
phenotype (Gosselin et al., 2014; Lavin et al., 2014). 
 
In mouse, expression levels of the cell surface F4/80 antigen define different macrophage 
subsets. Ontogenically, mouse macrophages can be classified into two broad groups 
based on their levels of expression of this cell surface marker F4/80, with F4/80low 
(originating from circulating monocytes during adult hematopoiesis) and F4/80high (from 
embryonic precursors) (Schultz et al., 2012; Pérez-de Puig et al., 2013). In the case of 
peritoneal macrophages, these two subpopulations are referred as large peritoneal 
macrophages (LPM, F4/80high), which are the higher fraction under basal conditions and 
are replaced by small peritoneal macrophages (SPM, F4/80high) upon antigenic 
stimulation (Ghosn et al., 2010; Okabe and Medzhitov, 2014; Rei et al., 2014). SPM are 
short-lived cells that can replace LPMs under inflammatory conditions, although LPMs 
do not seem to contribute to the SPM subpopulation (Cassado et al., 2015).  
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Figure 1. Origin and differentiation of myeloid cells. The figure displays the origin of different 
macrophage populations. Taken with permission from Marco Prinz & Josef Priller, Nat Rev Neurosc 15, 
300–312 (2014).  
 
 
 
 
The differential phenotype of macrophages across mouse tissues depends on a tissue-
specific transcriptional and epigenetic regulation of their genes, supporting once again 
the idea that microenvironmental signals dictate the programming, activation, phenotype 
and cellular function of macrophages (Álvarez-Errico et al., 2015).  
 
 
There are many transcription factors that regulate the functions of tissue-resident 
macrophages. For instance, the MAF transcription factor is more expressed in tissue 
macrophages than in monocytes, and both MAF and MAFB are essential for macrophage 
terminal differentiation (Lavin et al., 2015). Same applies to the peroxisome proliferator-
activated receptor-γ (PPARγ) in alveolar macrophages, GATA-binding protein 6 
(GATA6) in peritoneal cavity macrophages, Myocyte-specific enhancer factor 2C 
(MEF2c) in microglia, and Liver X receptor alpha (LXRA) in Kupffer cells and splenic 
F4/80hi
LPM
F4/80lo
SPM
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macrophages (Lavin et al., 2014, Rosas et al., 2014). Along PU.1, these transcription 
factors define phenotype and function of the macrophages in physiological or 
pathophysiological tissue-dependent contexts (Lawrence and Natoli, 2011).   
 
 
Peritoneal macrophages are an illustration of how tissue-derived signals can shape tissue-
resident macrophages functional identity. These macrophages can retain some levels of 
plasticity and adapt to new environmental cues, here peritoneal cavity macrophages, 
adoptively transferred into the lung microenvironment, downregulated Gata6 and 
upregulated Pparγ expression, although some transcripts remained fixed and retained the 
signature of the tissue of origin (Lavin et al., 2014; Okabe and Medzhitov, 2014).  
 
 
 
Macrophage Polarization 
 
 
Extravasation of circulating monocytes into inflamed tissues and the tumor 
microenvironment promote their differentiation into macrophages and their subsequent 
activation along a continuum of functional phenotypes.  At the extremes, these 
phenotypes are classically referred to as M1 and M2 polarization although intermediate 
phenotypes are more common in vivo (Lawrence and Natali, 2011; Murray et al., 2014; 
Xue et al., 2014 and Figure 2). Although this binary model represents a simple 
representation of macrophage activation, evidence in human and mouse macrophages 
indicates that macrophages display a broad functional spectrum of phenotypes in 
response to complex and ever changing signals in their specific microenvironments. 
Macrophage polarization is not a static state rather is an active process coordinated by 
genetic and molecular pathways (Martinez and Gordon, 2014; Williams et al., 2016). 
  
 
Activation of macrophages towards M1 occurs in response to Th1 cytokines and results 
in the production of pro-inflammatory cytokines (e.g., IL1β, IL12, TNFα, SOCS3). In 
turn, Th2 cytokines IL4 and IL13 trigger an M2-type phenotype with upregulation of 
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anti-inflammatory cytokines (e.g., IL10) and scavenger receptors (e.g., CD163, CD204, 
CD206/MRC1) (Sica and Mantovani, 2012; Arango Duque and Descoteaux, 2014).  
 
 
 
 
Figure 2. Classical binary model of macrophage polarization. The figure displays the archetypical 
macrophage activation that is seen in vitro.  
  
 
 
SOCS proteins 
 
 
Among the molecules that regulate macrophage polarization the eight members of the 
“suppressor of cytokine signaling” (SOCS) family proteins play an essential role in 
driving the inflammatory process. They are upregulated by cytokines or TLR ligands that 
cause anti- or pro-inflammatory activation. Thus, SOCS proteins regulate inflammation 
through several signaling cascades such as JAK-STAT, ERK, Notch, 
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phosphatidylinositol-3 kinase (PI3K), mitogen-activated protein kinases (MAPK), and 
NF-κβ pathways (Wilson, 2014; Wang et al, 2014). SOCS2 has a role in anti-
inflammatory macrophages limiting pro-inflammatory activation. Accordingly, IL4 
increases SOCS2 expression and macrophages deficient in SOCS2 are more 
inflammatory (Wilson et al., 2014). 
 
 
SOCS3 is rapidly induced in macrophages and has distinct roles in shaping macrophage 
activation and controlling immune and inflammatory responses. Since pro-inflammatory 
macrophages upregulate SOCS3, it is considered an M1-associated marker. In turn, 
human monocyte-derived macrophages where SOCS3 has been silenced showed elevated 
expression of M2 markers and decrease of M1 ones (Arnold et al., 2014). Likewise, 
murine macrophages with ablation of Socs3 display a decreased inflammatory response 
upon LPS stimulation and mice lacking Socs3 in myeloid cells are resistant to endotoxic 
shock and have a reduced production of pro-inflammatory cytokines (Kubo et al., 2003; 
Wilson, 2014). SOCS3 has also a role in phagocytosis and its knockdown enhances the 
phagocytic capacity of macrophages through PI3K signaling pathway and this increase in 
PI3K-AKT activity would influence M1-polarization, since PI3K negatively regulates 
pro-inflammatory cytokine production, enhances IL10 and suppresses response in 
myeloid cells exposed to LPS (Arnold et al., 2014). Of note, the regulation of pro-
inflammatory cytokines for SOCS3 occurs in a gene-specific manner. 
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Chapter II : Macrophage function 
 
 
 
 
As part of the innate immune response, several functions of myeloid cells, including 
phagocytosis, wound healing and remodeling tissues, have a role in mediating the 
inflammatory process. Here, I will briefly review below three of the main macrophage 
functions, namely, phagocytic activity, migration to reparation/infection foci and 
inflammation modulation.  
 
 
It is not clear if all these macrophage functions, could be complemented by non-resident 
monocyte-derived macrophages or whether specialized macrophage functions are 
specific to resident macrophage lineages. Peritoneal macrophages represent a widely 
used model for the study of macrophage functions since the peritoneal cavity serves as a 
readily accessible source of both monocyte-derived and resident macrophages offering 
the possibility to study phagocytosis, migration, and inflammation both in vitro and in 
vivo.  
 
 
 
Phagocytosis and migration  
 
 
Phagocytosis is an essential process in homeostasis and in immune defense and it 
consists in the recognition and engulfment of cell fragments, senescent cells or apoptotic 
cells. Moreover, it is a mechanism utilized by the immune system to eliminate pathogens 
or foreign particles	and	the phagocytic process is critical event in the active resolution of 
inflammation. Dysregulation of phagocytosis can lead to impaired host immune 
responses to pathogens and may even evolve to chronic inflammation and autoimmune 
response (Underhill and Goodridge, 2012).	 A number of cells in the organism have 
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phagocytic capabilities, however, macrophages are the most important phagocytic cells 
playing functions on apoptotic cell clearance and pathogen defense (Wynn et al., 2013). 
 
 
Macrophage polarization modulates their phagocytic capacity. Thus, M1 macrophages 
produce pro-inflammatory cytokines and promote the killing of bacterial pathogens by 
increasing bactericidal activity. On the other hand, the M2 phenotype is critical in 
defense of parasitic infections and tissue remodeling. M1-actived macrophages showed 
better phagocytic index of nanoparticles than M2 macrophages (Qie et al., 2016). The 
microenvironment also regulates the phagocytic activity of macrophages; thus, IL10 
derived from B cells or other cells in the peritoneum can impair phagocytosis, as well as 
age-related impair phagocytosis is an IL10-dependent phenomena (Martinez and Gordon, 
2014). There are also molecules specific to macrophages that affect their phagocytic 
activity. For instance, in mice lacking Pd-1, macrophages display improved bacterial 
clearance and mice presented decreased septic mortality (Huang et al., 2009). Moreover, 
macrophages from Vim (-/-) mice, an archetypal mesenchymal gene, had an improved 
phagocytic function (Mor-Vaknin et al., 2013). 
 
 
Migration is the fundamental locomotory mechanism for almost all cell types, but it is 
particularly important for immune cells as they maintain the homeostasis and defense of 
organism. Macrophages migrate more slowly that other immune cells, however, they 
respond rapidly in vivo and can travel considerable distances to inflammatory foci and 
they are therefore considered professional motile cells (Pixley, 2012).   
 
 
When monocytes and macrophages migrate in response to chemotactic stimuli the 
process is known as chemotaxis. Chemokines are secreted proteins, which act as 
sentinels at mucosal barriers and for the recruitment of the first line of innate immune 
effector cells to infection and inflammation foci. Chemokines bind to their respective 
receptors expressed on the cell surface of leukocytes, and that can be either constitutively 
expressed or induced in inflammatory conditions, in some cases the microenvironment is 
regulating their expression levels.	Monocytes respond to local stimuli such as cytokines 
and chemokines that direct migration toward inflammatory sites.  Experiments using 
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mice with targeted deletion of chemokines, demonstrate that hematopoietic circulating 
cells cannot maintain homeostasis or respond to pathologic conditions (Zamilpa et al., 
2011; Le Blanc and Mougiakakos, 2012).  
 
 
The chemokine CCL2 (also known as monocyte chemoattractant protein 1, MCP-1) is a 
small secretory protein that plays an important role in the chemotaxis of macrophages 
towards inflammatory foci and the tumor microenvironment. Its high affinity receptor, 
CCR2, can modulate HSC exit from the bone marrow and their release into the 
circulation. Upon extravasation, monocytes differentiate into a subset of monocytes that 
express CCR2 and are associated with immune defense against infection and the 
pathogenesis of inflammatory disorders. CCR2 signaling promotes pro-inflammatory 
monocyte migration into peripheral tissues in response to CCL2 (Italiani and Boraschi, 
2014; Deshmane et al., 2009). Binding of CCL2 to CCR2 leads to the internalization of 
CCL2 and triggers a number of signaling pathways such as PI3K, MAPK, Smad3, PKC 
and phospholipase C-γ. Stat3 and PI3K participate in endothelial activation associated 
with diapedesis of leukocytes during inflammation (Fang et al., 2012; Lim et al., 2014). 
Several signaling pathways that induces vascular permeability and extravasation, act 
downstream of CCR2; for instance, JAK2, Stat5, and p38MAPK. Thus, both CCL2 and 
its receptor CCR2 are involved in inflammation and in various diseases (Wolf et al, 
2012). In fact, blockade of CCL2-CCR2 signaling is an important therapeutic strategy in 
both inflammatory disorders and cancer therapy.  
 
 
Another chemokine that regulates the migration of monocytes and macrophages in 
homeostasis and pathologic process is the Colony-stimulating factor-1 (CSF1). CSF1 
stimulates actin polymerization and subsequent migration.  Moreover, the recruitment of 
macrophages to the proximity of tumors is mediated by CSF1 and CCL2 secreted by 
tumor cell. Furthermore, these factors are implicated in macrophage migration in several 
diseases, like arthritis, atherosclerosis, tumor growth, and metastasis (Pixley, 2012) and 
they, therefore, provide a promising therapeutic target. 
 
In sum, although migration is critical in immune response and homeostasis maintenance, 
it could also have a negative role in some diseases. In that line, many studies revealed 
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that reduction in macrophage motility is associated with a reduction in their capacity to 
enhance tumor cell invasion or inflammatory disorders. 
 
 
 
Role of macrophages in inflammation  
 
 
Once at tissues, macrophages can acquire different functions and phenotypes, which are 
modulated by signals from the environment. Inflammation occurs in several 
physiolopathological conditions and diseases. Its development as well as its resolution is 
closely related to macrophage function.  
 
 
Septic shock is a systemic inflammation that triggers a multiple organ dysfunction and is 
produced by bacterial infections or microbial toxins. Lipopolysaccharide (LPS) is the 
major cell wall component of Gram-negative bacteria that produce this inflammatory 
disorder. LPS stimulates immune cells through TLR4 interactions to produce several 
inflammatory cytokines whose overproduction can leads to death	(Roger et al., 2009).  
 
 
Endotoxin tolerance is the phenomenon in which immune cells, primarily monocytes and 
macrophages, transiently become hyporesponsive or tolerant upon repeated or prolonged 
exposure to LPS (Rajaiah et al., 2013). During disseminated endotoxin shock and acute 
sepsis, LPS induces a strong inflammatory response, but macrophages pre-exposed to 
LPS are hyporesponsive to a second LPS challenge and do not mount a full-fledged pro-
inflammatory reaction. Both inflammation and tolerance modulate macrophage functions 
and cannot be separated from the process of resolving inflammation, to avoid a non-
resolving inflammation such as cancer, inflammatory autoimmune diseases, or chronic 
inflammation that drives ongoing recruitment of monocytes to the inflammatory site 
(Biswas and Lopez-Collazo, 2009; Pena et al., 2011).  
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LPS tolerance models indicate that the macrophages have a rudimentary memory that 
makes them capable of recognizing the structural nature of foreign molecular patterns 
and discern the history and concentration of foreign stimulants, this can explain the 
paradigm of endotoxin priming and tolerance (Seeley and Ghosh, 2016).  
 
 
In a pivotal study, Freudenberg and Galanos (1998) demonstrate that macrophages have 
an essential role of in LPS-tolerance induction through a mice model defective for the 
LPS signaling receptor. When these mice received adoptive transfer of LPS-sensitive 
macrophages from a wild-type mouse, they became susceptible to lethal challenges of 
LPS. However, when transplanted mice were first challenged with non-lethal doses of 
LPS and then subjected to a lethal dose of LPS, all mice survived, thereby showing that 
macrophages are the primary mediators of endotoxin tolerance (Freudenberg and 
Galanos, 1988, Biswas et al., 2007; Deng et al., 2013).  
 
 
Subsequent in vitro studies have shown the induction of endotoxin tolerance in human 
monocytes and macrophages with reduced TNF expression. Likewise, compared to 
monocytes from healthy donors, those from sepsis patients showed an increase in the 
expression of anti-inflammatory cytokines like IL10 and TGFβ (Adib-Conquy et al., 
2006). Consequently, endotoxin tolerance is considered to be a physiological negative 
feedback response that protects the host against uncontrolled inflammation.   
 
 
There are two classes of genes involved in tolerance, “tolerizable genes” that are 
abrogated in tolerance including TNFα, and “non-tolerizable genes” that are upregulated 
in tolerance and include anti-inflammatory and wound repair genes, such as IL10 and 
matrix metalloproteinase 9  (MMP9) (Shalova et al., 2015; Alvarez-Errico et al., 2015).  
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Chapter III :  The tumor microenvironment 
 
 
 
Within both healthy tissues and solid tumors it is possible to distinguish the functional 
section or parenchyma from the supporting stroma, being both separated by the basal 
lamina. The stroma includes a wide array of cell types including endothelial cells, 
perivascular cells, adipocytes, fibroblasts, and immune cells, especially macrophages. In 
tumors, the stroma is often referred as the tumor microenvironment (TME) and becomes 
invaded by tumor cells once the basal lamina is disrupted. Stromal cells in the TME 
interact closely with tumor cells and mutually affect each other. For instance, factors 
released by the TME can either promote or inhibit tumor cell survival, invasiveness, and 
metastatic dissemination, as well as access and therapeutic responsiveness (Turley et al, 
2015).  
 
 
In turn, malignant cells activate macrophages and fibroblast in the TME that changes 
constantly during tumor progression according to the oncogenic signals it receives from 
the tumor (Kim eta al., 2007). Different stimuli like hypoxic conditions, growth factors, 
and immunosuppressive cytokines supplied by the TME, endow tumor-associated 
macrophages (TAMs) with pro-tumor characteristics that facilitate tumor development. 
The capacity of carcinomas to recruit and activate TAMs largely depends on malignant 
cells having acquired an undifferentiated phenotype with loss of epithelial markers and 
expression of mesenchymal markers as part of the so-called epithelial-to-mesenchymal 
transition (EMT). In turn, tumor cells, particularly those than have undergone an EMT 
secrete factors that modulate and activate cells in the TME (Su et al., 2014).				
In epithelial tissues that have dedifferentiated and undergone EMT, cells at the invasive 
tumor edge secrete cytokines, chemokines, growth factors and proteases that promote 
angiogenesis, remodel the extracellular matrix and can activate stromal cells (Rosen and 
Jordan, 2009).  
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Tumor-associated macrophages 
 
 
TAMs are the largest component of the TME and despite being a highly heterogeneous 
population, they share some characteristics with M2 macrophages, such as wound 
healing and angiogenic proprieties. Nevertheless, the transcritpome of M2 macrophages 
and TAMs is not completely overlapping (Xue et al., 2014). It is possible to find 
different TAMs populations within the same tumor with a combination of both pro-
inflammatory and anti-inflammatory gene expression. Moreover, macrophages involved 
in cancer-initiating inflammatory process may begin acting as anti-tumoral cells, 
however, once tumors are established, macrophages are educated to become pro-tumoral 
(Franklin et al., 2014; Noy and Pollard, 2014).  
 
 
The mechanisms by which macrophages switch from a tumor suppressing phenotype to 
tumor promoting one are not fully understood. It has been suggested that environmental 
signals such as secreted tumor factors or hypoxia may mediate this transition. TAMs 
accumulate in regions of hypoxia within growing tumors, and their recruitment is 
mediated by an upregulation of macrophage chemoattractants (Wen et al., 2015). CCL2 
is secreted in response to a variety of inflammatory stimuli; however, the primary source 
of CCL2 is unclear. It is possible that locally produced CCL2 derived from tumor or 
stromal cells enters the systemic circulation. In most tumor cells, CCL2 expression is 
positively correlated with monocyte infiltration. These monocytes can be polarized to an 
anti-inflammatory/pro-angiogenic phenotype becoming in TAMs that can promote 
immunosuppression in the tumor niche. Furthermore, CCL2 blocks apoptosis and 
enhanced migration in mammary carcinoma cells. Clinical evidence shows that elevated 
levels of CCL2 associate to poor prognosis in most of cancers (Ostuni et al., 2015).  
 
TAM accumulation in the TME also correlates with angiogenesis and the subsequent 
acquisition of an invasive phenotype (Figure 3). At the same time, angiogenesis is 
facilitated by TAM-derived proteases (e.g. matrix metalloproteinases, plasmin, 
urokinase-type plasminogen activator/uPA and urokinase-type plasminogen activator 
receptor/uPAR) that are released in tumor sites, as extracellular proteolysis, which is a 
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requirement for blood vessel formation. For example, TAM-derived MMP9 induces the 
release of vascular endothelial growth factor-α (VEGFα) that is crucial for the angiogenic 
switch.  
 
 
These enzymes also facilitate tumor invasion reorganizing the extracellular matrix and 
degrading the basement membrane. Moreover, inhibition of the MMP9 in macrophages 
blocked the release of VEGF and thereby inhibited angiogenesis and tumor growth in a 
cervical cancer mouse model (Ebrahem et al., 2010; Guiraudo et al., 2004). Likewise, 
expression of hypoxia-inducible factor (HIF1α) in cells in response to hypoxia promotes 
the expression of VEGF, matrix metalloproteinase 7 (MMP7), and MMP9 in TAMs 
(Hagerling et al., 2015; Condeelis and Pollard, 2006). Other example is Wnt Family 
Member 5A (WNT5A) that participate in Wnt/β-catenin-independent pathway, in 
macrophages induce a tolerogenic phenotype and is associated to transition from 
tumoricidal to tumor-promoting TAM profile (Pukrop et al., 2006; Bergenfelz et al., 
2012). 
 
 
 
ZEB1 and EMT 
 
 
EMT plays an important role during embryonic development, and it also contributes in 
tumor initiation and progression. Tumor cells undergoing EMT acquire a pro-invasive 
and stem-like phenotype and exhibit enhanced self-renewal properties, increased 
tumorigenic potential and increased chemotherapy resistance. Expression of EMT 
markers in tumors correlates with poorer prognosis (Tsai and Yang, 2013).  
 
 
EMT is driven by transcription factors of the TWIST, SNAIL, and ZEB families (Nieto 
et al., 2016). Of all EMT factors, the two members of the ZEB family, ZEB1 and ZEB2, 
present the best inverse correlation with epithelial markers and often function as 
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downstream effectors of Snail and Twist factors (Taube et al., 2010).  ZEB1 (also known 
as δEF1), which is expressed by malignant cells at the invasive front of carcinomas is a 
key inducer of EMT in cancer cells. ZEB1 inhibits the terminal differentiation of a 
number of cell types (e.g., epithelial cells, myoblasts, chondroblasts, osteoblasts), and its 
levels need to be downregulated for differentiation to occur (Brabletz and Brabletz, 2010; 
Siles et al., 2013). 
 
 
Despite ZEB1 has never been studied in myeloid cells, other EMT transcription factors 
have shown modulate myeloid differentiation or activation. Since, Snail and Twist have a 
role in anti-inflammatory macrophages (Zhang et al., 2014; Zheng et al., 2015), and 
ZEB2 regulates dendritic cells development (Scott et al., 2016) it was expected that 
ZEB1 would be playing a role in myeloid cells. Therefore, I decided to inquire whether 
ZEB1 is expressed and has a role in macrophage activation and function. ZEB1 contains 
multiple independent domains to interact with other transcriptional regulators and thus 
ZEB1 directly activates or represses gene expression by binding to the regulatory regions 
of its target genes (Postigo and Dean, 1999; Postigo et al., 2003)  
 
 
Macrophages are localized primarily at the periphery of the TME and around blood 
vessels but decrease in number toward the center (Lewis and Pollard, 2006; Quail and 
Joyce, 2013).  These observations suggest that TAMs modulate the phenotype of tumor 
cells located in the neighboring microenvironment and the occurrence of EMT in tumors 
may, therefore, be transient and highly dependent on the local microenvironment. 
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Figure 3. Crosstalk between cancer cells and myeloid cells in the TME. The TME is essential for tumor 
growth and invasion through chemokine signaling from tumor cells that recruit immature monocyte that 
later mature into TAMs to promote tumor aggressiveness. 
 
 
This relation between EMT and immune cells infiltration is the hallmark of many cancer 
types, including inter alia ovarian, pancreatic and prostate carcinoma.  
 
 
 
Ovarian Cancer  
 
Epithelial ovarian cancer (EOC) is the seventh most frequent cancer diagnosed in women 
accounting approximately 140,000 deaths and 200,000 patients being diagnosed annually 
worldwide  (Brown and Palmer, 2009). EOC has a poor prognosis largely because of the 
presence of local and distant metastases in the majority of patients at diagnosis. 
Treatment options for late-stage disease are limited since despite a positive response to 
Tumor-Associated Macrophages                               INTRODUCTION                                                 
CCR2
CCR2
CCR2
CCL2
CSF1
CSF2
Mo
no
cy
te 
re
cr
uit
me
nt
TAM differentiation
CCR2
CD163 CD206
Angiogenesis
Invasion
Chemoresistance
EMT
MMP9
IL10
VEGF
TNF
Tumor Progression
	 26	
platinum-based therapies, eventually, patients become resistant to chemotherapy 
(Lengyel, 2010; Liu and Matulonis, 2014).  
 
 
Ovarian carcinomas are classified in different histological subtypes, with the high-grade 
serous ovarian carcinoma (HGSC) as the predominant OC (80-85%), followed by 
endometrioid tumors (10% of cases), while clear cell and mucinous carcinomas are rarer. 
These histological subtypes correspond to different epidemiological and, mutational 
characteristics, sites of origin and response to chemotherapy (Hasan et al., 2015). HGSC 
has a poorly differentiated phenotype and is highly proliferative; and given the lack of 
early symptoms, if is most often diagnosed advanced clinical stages (III and IV), and has 
therefore poor prognosis and survival rates (Chen, et al., 2014). HGSCs lines are widely 
used in ovarian cancer research, and of late it has been demonstrated the association 
among ZEB factors and in vivo tumor growth using a panel of these HGSCs lines 
(Medrano et al., 2017).   
 
 
Advanced OCs develop peritoneal ascites, which contributes to the dissemination and 
spread of tumor cells throughout the peritoneal cavity. Ascitic fluid is also implicated in 
resistance to chemotherapy (Kipps et al., 2013). Chronic inflammation during the 
development of ovarian cancer is a key factor in tumor progression as it prevents the 
maturation of myeloid cells and promotes their immunosuppressive polarization. In 
patients with advanced OC, it is possible to detect TAMs in the primary lesion as well as 
in the ascitic fluid, and are associated with worst prognosis and tumor dissemination in 
the peritoneal cavity (Reinartz et al., 2014). 
 
 
As in other cancers, TAMs are the most abundant leukocytes cells infiltrating in human 
ovarian tumors. Pro-tumor TAMs expressing pro- and anti-inflammatory markers such as 
CD163 and CD206 are recruited from circulating monocytes by ovarian tumors that 
express chemoattractant factors CCL2 and CSF1 (Colvin, 2014). CCL2 is overexpressed 
in ovarian tumor cells, but not in TAMs, also CSF1 expression is higher in malignant 
cells. Indeed there is a strong correlation between the number of infiltrating TAMs and 
the malignancy of OC. Likewise, peripheral blood monocytes and ascitic TAMs in 
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women with ovarian cancer have a dedifferentiated phenotype compared to cells from 
healthy. The expression of M2-markers or cytokines produced by TAMs are prognostic 
factors of poorer prognosis in human ovarian cancer. Thus, both CD163 and IL10 are 
correlated with progression-free survival and higher tumor grade (Colvin et al., 2014). 
 
 
TAMs form spheroids and secrete cytokines that promote the lymphangiogenesis process 
(Zhang and Thian, 2014; Yin et al., 2016). Co-culture experiments or culture with 
conditioned medium have shown that ovarian tumor cells can polarize macrophages 
towards an M2-protumoral phenotype, while TAMs can modulate ovarian cancer cells to 
more aggressive and chemoresistant phenotype, indicating the importance of this relation 
tumor cell-TAM in ovarian cancer progress (Lengyel, 2010; Colvin, 2014). Altogether, 
this evidence prompted me to use ovarian cancer as the experimental model for my PhD 
project. 
 
 
 
Ovarian Cancer models  
 
 
In xenograft cancer models, cells are injected into immunocompromised mice such as 
nude, SCID or NOD/SCID to enable the cells to engraft without being eliminated by the 
immune system (Bobbs et al., 2015). However, this model has some disadvantages, as it 
does not reflect what happens in clinical practice since the tumor is not located on the 
same site or in contact with peritoneal microenvironment, and immune response cannot 
be studied.  
 
 
Patient derived xenografts (PDX) models use human tumor engrafted in 
immunodeficient mice. This model offers a powerful tool to recapitulate woman ovarian 
cancer patient histotype with whole genome expression and evaluate accurately treatment 
response. Nevertheless PDX has the drawback that require the use of immunodeficient 
mice where it is not possible to study the role of the immune system and the tumor-
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stroma crosstalk, it is difficult to achieve tumor engraftment and it is more costly and 
time-consuming than other models (Siolas and Hannon, 2013). 
 
 
Some of these disadvantages can be overcome in syngeneic models, which use 
immunocompetent mice where mouse ovarian surface epithelial (MOSE) cells are 
isolated from the ovaries of wild-type normal mice then cultured in vitro for a prolonged 
period until to be spontaneously transformed or by inserting genetic modifications in 
healthy cells. These transformed cells are injected into recipient mice and will be able to 
form tumors. This model provides the opportunity to study the tumor microenvironment, 
tumor-stromal cells crosstalk, tumor-secreting factors and immune cell infiltration. 
Likewise, some syngeneic models use genetically modified cells and highly metastatic 
cell lines stably expressing luciferase for monitoring disease (Fong and Kakar, 2009). 
Overall, syngeneic models present tumors with similar histopathologic characteristics 
those observed in women with ovarian cancer as also development of closely resembling 
human disease. Roby et al. (2000) isolated and culture MOSE cells, which spontaneously 
were transformed in vitro with repeated passages. This is the origin of ID8 cell line that 
has been widely used as an experimental mouse model of ovarian cancer as it resembles 
the late metastatic stage of human HGSC (Roby et al., 2000). Like in human HGSC, ID8 
tumor deposits are highly infiltrated with immune cells, mainly macrophages. 
 
 
This ID8 model is particularly useful to study of interactions between tumor cells and 
their microenvironment, ID8 injected into the ovarian bursa of C57BL/6 mice showed 
that interaction between tumor cells and the ovarian stroma results in increased 
expression of proliferative and survival markers, including phosphorylated Akt, 
proliferating cell nuclear antigen, and Bcl-2 (Greenaway et al., 2008). In vivo passages of 
ID8 cells into naive mice increased their aggressiveness as defined by a shorter lag to 
develop both tumor and ascites and enhanced morbidity (Cai et al., 2015). Both studies 
highlight the interplay between tumor cells and their microenvironment in the 
modulation of tumor cell properties.  
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This dissertation aimed to study the role of ZEB1 in macrophages and had two specific 
objectives: 
 
 
1. Characterize the expression and function of ZEB1 in macrophages during 
monocyte-macrophage differentiation and in macrophage homeostasis and activation. 
 
 
2. Characterize the expression and function of ZEB1 in tumor-associated 
macrophages and in their crosstalk with cancer cells. 
 
 
 
 
To address these goals, I used a wide number of techniques, namely, high throughput 
analysis (RNA sequencing) and different functional assays in a transgenic mouse model 
harboring the deletion one Zeb1 allele [Zeb1 (+/-)] and the ID8 syngeneic mouse model 
of ovarian cancer. 
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Antibodies 
 
Antibodies used in this article originated as follows: anti-human/mouse ZEB1 (Clones H-
102 and E-20, Santa Cruz Biotechnology, Dallas, TX, USA), anti-mouse β-Actin (Clone 
C4, Santa Cruz Biotechnology), anti-mouse F4/80 conjugated to APC (clone BM8, 
reference 17-4801; Bioscience Inc., San Diego, CA, USA), anti-mouse CD11b 
conjugated to PE (clone M1/70.15, reference 22159114; Immuno Tools GmbH, 
Friesoythe, Germany), anti-mouse CD45 conjugated to PerCP/Cy5.5 (clone 30-F11, 
reference 103131; BioLegend, San Diego, CA, USA), anti-human ZEB1 (clone 
HPA027524, Sigma-Aldrich, St. Louis, MO, USA), anti-human CCL2 (clone 2D8, 
Invitrogen, Thermo Fisher, Carlsbad, CA, USA), anti-human CD163 (clone 10D6, Leica 
Biosystems, Newcastle Upon Tyne, UK), anti-human CCR2 (clone 48607, R&D 
Systems, Minneapolis, MN, USA) and anti-human MMP9 (clone E-11, sc-393859, Santa 
Cruz Biotechnology). 
 
 
In addition, the study used the following secondary antibodies peroxidase-AffiniPure 
donkey anti-Mouse IgG (H+L) (reference 715-035-151), peroxidase-AffiniPure goat 
Anti-Rabbit IgG (H+L) (reference 111-035-144) and mouse gamma globulin (reference 
015-000-002), all purchased from Jackson ImmunoResearch Europe (Newmarket, UK).  
 
 
 
Mouse models 	
Wild-type C57BL/6J and Lyz2Cre mice were obtained from Jackson Laboratories (Bar 
Harbor, ME, USA). Mice heterozygous for Zeb1 (Zeb1 (+/-) mice) were obtained from 
Dr. Douglas S. Darling (University of Louisville, KY, USA) and Dr. Y. Higashi 
(Institute for Development Research, Kasugai-shi, Aichi, Japan) (Takagi et al., 1998). 
Socs3f/f and Socs2-/- mice were obtained from D.J. Hilton (Royal Melburne Hospital, 
Victoria, Australia). All animal procedures were approved by Animal Experimentation 
Ethics Research Committee at the University of Barcelona. 
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Isolation and culture of normal mouse primary cells  
 
Bone marrow total cells (BMTCs) were obtained from 6-8 weeks-old C57BL/6 wild-type 
and Zeb1 (+/-) mice (Takagi et al., 1998) and differentiated into macrophages as 
described (Zhang et al., 2008). Briefly, femur and tibia bone marrows were flushed with 
Phosphate buffered saline (PBS) and BMTCs collected were centrifuged and 
resuspended fin Dulbecco’s modified Eagle Medium (DMEM) (Lonza, Basel, 
Switzerland) supplemented with 10% FBS (Sigma-Aldrich. St. Louis, MO), and 1% 
penicillin-streptomycin (Pen/Strep) (Lonza), medium hereafter referred as complete 
medium. To generate bone marrow–derived macrophages (BMDM), BMTCs were 
cultivated with 20 ng/ml of recombinant M-CSF (ImmunoTools GmbH, Friesoythe, 
Germany) during 6 days. Every 2 days, half of the medium was replaced with fresh 
medium supplemented with M-CSF. Identical results were obtained when BMTCs were 
cultivated with 40% of supernatant from L929 culture cells (ATCC, Manassas, VA, 
USA) stably transfected with M-CSF expression vectors.  
 
 
Peritoneal macrophages were isolated from 6-8 week-old Zeb1 (+/+) and Zeb1 (+/-) mice 
as per standard protocols (Zhang et al., 2008). Briefly, mice were euthanized and the 
peritoneal cavity was washed twice with 6 ml of ice-cold PBS supplemented with 3% 
FBS. Cells from the peritoneal lavage were centrifuged at 400 x g for 10 min at 4ºC and 
erythrocytes in the cell suspension were osmotically lysed by incubation with Red Blood 
Cell Lysis Buffer (Sigma-Aldrich), followed by washing with PBS and resuspension in 
PBS or complete medium. Peritoneal cells were then sorted for F4/80 and CD11b cell 
surface expression and isolated cells were then either examined for mRNA or cell surface 
markers expression or tested for the indicated functional assays.  
 
 
 
Isolation and culture of human primary cells 
 
Use of human samples was approved by the Ethics Committee for Clinical 
Experimentation at Hospital Clinic of Barcelona (Barcelona, Spain). Peripheral blood 
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mononuclear cells were obtained from buffy coats extracted from healthy donors and 
were separated by density gradient centrifugation with Lymphocyte Separation Medium 
(Lonza, Basel, Switzerland). Monocytes were purified from total PBMCs by magnetic 
cell sorting with Dynabeads® CD14 (Dynal®, Thermo Fisher, Waltham, MA, USA). 
Purified human monocytes (> 92% CD14+) were cultured for 7 days in RPMI 1640 
(Lonza) supplemented with 10% FBS (Sigma-Aldrich. St. Louis, MO), 1% penicillin-
streptomycin (Pen/Strep) (Lonza) and 20 ng/ml of human recombinant M-CSF/CSF1 
(ImmunoTools) or human recombinant GM-CSF/CSF2 (ImmunoTools GmbH). 
 
 
 
Flow cytometry analysis and sorting (FACS) 
 
Cells were first blocked for Fc receptors with mouse gamma globulin (Jackson 
ImmunoResearch Europe). Cells were then incubated in PBS with 2% FCS for 45 min at 
4˚C with the corresponding fluorochrome-labeled antibodies. Expression of cell surface 
proteins was assessed in a BD FACSCanto™ II analyzer (BD Biosciences, San Jose, CA, 
USA). Wherever indicated, cells were sorted for specific subpopulations in a FACS 
Aria™ II cell sorter (BD Biosciences) for subsequent experimentation. The acquired data 
were analyzed using FlowJo for Windows, version 7.6.1 (FlowJow, Ashland, OR, 
USA).   
 
 
 
RNA extraction and quantitative real time PCR 
 
Total RNA was extracted with RNAzol® RT reagent (Sigma-Aldrich) or TRIzol® (Life 
Technologies, Thermo Fisher Scientific) and reverse transcribed with oligodT using 
High-Capacity cDNA Reverse Transcription Kit (Life Technologies, Thermo Fisher 
Scientific). mRNA levels were then determined by quantitative real-time PCR (qRT-
PCR) at 60 ºC using GoTaq® qPCR Master Sybr Green Mix (Promega Corp., Madison, 
WI, USA). Results were analyzed using Opticon Monitor 3.1.32 software (Bio-Rad, 
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Hercules, CA, USA) by ΔΔCt method and normalizing values with respect to mouse 
Gapdh or human GAPDH housekeeping gene. DNA primers used in qRT-PCR were 
purchased from Sigma-Aldrich and their sequences are described in Table 1. The 
nomenclature for mouse and human genes adheres to MGI (Mouse Genome Informatics, 
http://www.informatics.jax.org/) and HGNC (HUGO Gene Nomenclature Committee, 
http://www.genenames.org/), respectively.  
 
 
 
Target 
gene 
 
 
Forward 5’ →  3’ 
 
Reverse 5’ →  3’ 
 
Ref 
Aldh1a1 GACAGGCTTTCCAG
ATTGGCTC 
AAGACTTTCCCACC
ATTGAGTGC 
Levi et al. 2009 ,
Ccl2 GGGATCATCTTGCT
GGTGAA 
AGGTCCCTGTCATG
CTTCTG 
Aurora et al., 
2014 
Ccr2 AGCACATGTGGTGA
ATCCAA 
TGCCATCATAAAGG
AGCCA 
Kitamoto et al., 
2013 
Cd163 TGTATGCCCTTCCTG
GAGTC 
TGTGCAGTGTCCAA
AAGGAG 
Li et al., 2015 
Cdh1 AGACTTTGGTGTGG
GTCAGG 
ATCTGTGGCGATGA
TGAGAG 
Lin et al., 2012 
Gapdh CGACTTCAACAGCA
ACTCCCACTCTTCC 
TGGGTGGTCCAGGG
TTTCTTACTCCTT 
De Freitas et al., 
2012 
Il1b TGACGTTCCCATTA
GACAACTG 
CCGTCTTTCATTACA
CAGGACA 
Arnold et al., 
2007 
Cxcl15/Il8 AGAGGCTTTTCATG
CTCAACA 
CCATGGGTGAAGGC
TACTGT 
Zhang et al., 
2017 
Il10 TGTCAAATTCATTC
ATGGCCT 
ATCGATTTCTCCCCT
GTGAA 
Kwon et al., 2014 
Kit GACGCAACTTCCTT
ATGATC 
TGGTTTGAGCATCTT
CACGG 
Leong et al., 
2008 
Mdr1 TCCACAGAAAGCAA
GACCAAGAG 
CCAGAGGCACATCT
TCATCCA 
Rankin et al., 
2006 
Mmp9 TAAGGACGGCAAAT
TTGGTT 
CTTTAGTGGTGCAG
GCAGAG 
Nakasone et al., 
2012 
Mrc1 AAGGCTATCCTGGT
GGAAGAA 
AGGGAAGGGTCAGT
CTGTGTT 
Colegio et al., 
2014 
Nfkb1 GAACGATAACCTTT
GCAGGC 
TTTCGATTCCGCTAT
GTGTG 
Eisele et al., 2013 
Retnla GCTGATGGTCCCAG
TGAATAC 
CCAGTAGCAGTCAT
CCCAGC 
Arranz et al., 
2012 
Tnf TTTCGATTCCGCTAT
GTGTG 
CCACCACGCTCTTCT
GTCTAC 
Eisele et al., 2013 
Vegf AATGCTTTCTCCGCT
CTGAA 
GATCATGCGGATCA
AACCTC 
Wei et al., 2015 
Vim CCAACCTTTTCTTCC
CTGAA 
TGAGTGGGTGTCAA
CCAGAG 
Olmeda et al., 
2007 
Zeb1 AACTGCTGGCAAGA
CAAC 
TTGCTGCAGAAATT
CTTCCA 
Siles et al., 2013 
hZEB1 AGCAGTGAAAGAGA
AGGGAATGC 
GGTCCTCTTCAGGT
GCCTCAG 
Sanchez Tillo et 
al., 2011 
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Table 1. Primers used in qRT-PCR assays  
 
 
 
 
 
 
RNA interference and stable transfection of mouse and human primary 
cells 
 
Mouse and human macrophages were transfected with 200 nM of either siRNA control 
or siRNAs specific against mouse Zeb1 or human ZEB1 with Lipofectamine® RNAimax 
(Thermo Fisher, Waltham, MA) as per manufacturer’s instructions. siRNA 
oligonucleotide duplexes were purchased from Sigma-Aldrich and their sequences are 
detailed in Table 2.  
 
 
Zeb1 was overexpressed in peritoneal macrophages by transduction of lentiviral particles 
generated from a plasmid encoding for mouse Zeb1 (LP-Mm05622-Lv103-0200-P) 
(Tebu-bio, Le-Perray-en-Yvelines, France) kindly provided by Dr D.C. Dean (University 
of Louisville, Louisville, KY, USA). 
 
 
 
 
Table 2. siRNA oligonucleotide sequences 
 
 
hGAPDH TGCACCACCAACTG
CTTAGC 
GGCATGGACTGTGG
TCATGAG 
Sanchez Tillo et 
al., 2011 
hCD163 AGGATGCTGGAGTG
ATTTGC 
CCAGCCGTCATCAC
ATATTG 
Medina et al., 
2011 
hWNT5A CTTGGTGGTCGCTA
GGTATG 
TCGGAATTGATACT
GGCATT 
Keller et al., 
2008 
 
siRNA 
 
Gene 
Targeted 
 
 
Sense strand sequence 
 
Reference 
siCtl 
 
N/A UAUAGCUUAGUUCGUA
ACCTT 
Siles et al., 
2013 
siZeb1-A Mouse Zeb1 & 
Human ZEB1 
AACUGAACCUGUGGAU
UAUTT 
Siles et al., 
2013 
siZeb1-B Mouse Zeb1 GACCAGAACAGUGUUC
CAUGUUUAATT 
Siles et al., 
2013 
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RNA sequencing and data analysis  
 
Peritoneal macrophages (CD45+, CD11b+, F4/80+) from Zeb1 (+/-) and Zeb1 (+/-) 6-to-8-
weeks old female mice—6 for each genotype—were isolated and their RNA extracted 
using RNAzol® RT reagent (Sigma-Aldrich) as per manufacturer’s instructions. RNA 
was quantified and its quality (RNA integrity numbers ≥ 8.5) assessed on a Agilent 2100 
Bioanalyzer (Agilent, Santa Clara, CA, USA). Part of the RNA samples were reverse 
transcribed as described above to examine Zeb1 expression. To obtain at least 1 µg of 
RNA required in the preparation of libraries in triplicate, two samples from each 
genotype were pooled.  
 
 
Libraries construction and RNA sequencing was performed at the Centro Nacional de 
Regulacion Genomica (Barcelona, Spain). Libraries were prepared from total RNA with 
the TruSeq®Stranded mRNA LT Sample Prep Kit (Illumina Inc., San Diego, USA 
Rev.E, October 2013). Briefly, 0.5 µg of total RNA was used for poly-A based mRNA 
enrichment with oligo-dT magnetic beads. The mRNA was fragmented (resulting RNA 
fragment size was 80-250nt, with the major peak at 130nt) and the first strand cDNA 
synthesis was done by random hexamers and reverse transcriptase. The second strand 
cDNA synthesis was performed in the presence of dUTP instead of dTTP, to achieve the 
strand specificity. The blunt-ended double stranded cDNA was 3´adenylated and 
Illumina indexed adapters were ligated. The ligation product was enriched with 15 PCR 
cycles and the final library was validated on an Agilent 2100 Bioanalyzer with the DNA 
7500 assay. Libraries were sequenced on HiSeq2000 (Illumina, Inc) in paired-end mode 
with a read length of 2 x 76bp using TruSeq SBS Kit v3-HS. 
 
 
 Over 20 million paired-end reads were generated for each sample in a fraction of a 
sequencing flowcell lane, following the manufacturer’s protocol. Image analysis, base 
calling and quality scoring of the run were processed using the manufacturer’s software 
Real Time Analysis (RTA 1.13.48) and followed by generation of FASTQ sequence files 
by CASAVA. Reads were mapped against the mouse reference genome (GRCm38) with 
STAR (Dobin and Gingeras, 2015) using the ENCODE parameters for long RNA. Gene 
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quantification was performed with RSEM (Li and Dewey, 2011) with default options and 
gencode version 11 mouse annotation. Normalization and differential expression analysis 
was done with edgeR (Robinson et al., 2010) with default options. GO and KEGG 
enrichment analyses were performed with the beta version of DAVID database 
(http://david.ncifcrf.gov/).  
 
 
All 412 differentially expressed (DE) genes were grouped in a Hierarchical clustering 
with Genesis software (http://genome.tugraz.at, Sturn et al. 2002) and some of them were 
examined using the gene-gene and gene-protein network tool GeneMANIA plataform 
(Mostafavi et al., 2008). 
 
 
 
Western blot  
 
Peritoneal macrophagess were harvested, washed with ice-cold PBS and resuspended in 
RIPA lysis buffer (150 mM NaCl, 50 mM Tris pH 8, 1 % NP40, 0.5 % SDS, 2 mM 
EDTA) containing protease inhibitors (10 µg/ml aprotinin, leupeptin, pepstatin A and 
PMSF) as previously described (Sánchez-Tilló et al., 2011). Lysates were sonicated in an 
Ultrasonic Liquid Processor (Misonix Inc.), clarified by centrifugation and quantified by 
Bradford assay. Lysates were then boiled and loaded onto 10 % polyacrylamide gels and 
transferred to a PVDF membrane (Immobilon-P, Millipore, Bedford, MA, USA). 
Membranes were blocked with 5% non-fat milk and blotted with the indicated primary 
antibodies overnight at 4 ºC. Detection was done after incubation with HRP-conjugated 
secondary antibodies. Reaction was developed with SuperSignal West Pico 
Chemilluminescent Substrate (Thermo Fisher Scientific). 
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In vivo phagocytosis assay 
 
5 × 106 ID8-GFP cells or ID8 labeled with CFSE cells were injected into the peritoneal 
cavity of Zeb1 (+/+) and Zeb1 (+/-) mice.  Mice were euthanized 3-4 h later and 
peritoneal exudate cells were collected by lavage with 6 ml of ice-cold PBS 
supplemented with 3% FBS twice. Cells were then analyzed in a BD FACSCanto™ II 
analyzer (BD Biosciences) and in vivo phagocytosis was determined by the percentage of 
GFP+ cells out of the total of those previously gated as positive for F4/80.  
 
 
 
In vitro macrophage migration  
  
In vitro migration of macrophages was assessed through two approaches. First, using a 
wound-healing assay. Briefly, 1 x 106 peritoneal macrophages in complete medium were 
seeded in 6-well plates and incubated overnight. A defined wound field was then created 
with a pipette tip and cell migration across the gap was monitored by light microscopy 
(Olympus, Hicksville, NY) for up to 24 h.  
 
 
 Secondly, macrophage migration was examined with a Transwell® migration assay. 
Briefly, 0.5 x 106 peritoneal macrophages were labeled with 5 mM Carboxy-fluorescein 
diacetate succinimidyl ester (CFSE, Sigma-Aldrich). After washing once with complete 
medium and thrice with PBS, cells were resuspended in 200 µl of DMEM supplemented 
with 2.5% FBS and added on top of 6.5 mm diameter/8 µm pore polycarbonate 
Transwell® inserts (Corning Inc., Tewksbury, MA, USA), which in turn were placed 
over a 24-well plate. The lower chamber was filled with 0.6 ml of complete medium 
containing 80 ng/ml mouse recombinant CCL2 (mrCCL2) (ImmunoTools GmbH). 
 
 
 After 2 hrs, macrophage migration was assessed by the CFSE fluorescence signal 
measured in a Modulus II GloMax®-Multi-Detection System microplate reader 
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(Promega Corp., Madison, WI, USA). Macrophage migration was then expressed as 
relative fluorescence units (RFU) with respect to a 100% value represented by the 
fluorescence of the cell suspension initially loaded on top of the Transwell® insert. RFU 
values are expressed as the mean with their standard errors of five mice for each 
genotype.  			
In vivo migration 
 
Briefly, for in vivo migration of myeloid precursors and macrophages, bone marrow total 
cells (BMTCs) or bone marrow-derived macrophages (BMDMs) from Zeb1 (+/+) and 
Zeb1 (+/-) mice were first labeled with CFSE.  Wild-type mice were then injected i.p. 
with 1 ml of 3% thioglycollate (Sigma-Aldrich) before either 2-3 x 107 CSFE-labeled 
BMTCs or 5-6 x 106 CSFE-labeled BMDMs were then injected i.v. into these Zeb1 (+/+) 
recipients. After 48 h mice were sacrificed and the mobilization and recruitment of these 
cells into the peritoneal cavity was then assessed by CSFE expression in peritoneal 
lavage cells by FACS analysis. 
 
 
 
In vivo monocyte maturation  
  
In vivo monocyte maturation was carried out as described (Tsou et al., 2007). Briefly, 
bone marrow total cells (BMTCs) from Zeb1 (+/+) and Zeb1 (+/-) mice were first labeled 
with CFSE. 2-3 x 107 CSFE-labeled BMTCs were inoculated i.v. into Zeb1 (+/+) 
recipients. For in vivo mobilization and differentiation of myeloid precursors into 
macrophages, either 1 ml of conditioned medium from L929/M-CSF cells or 1 µg of 
recombinant CCL2 (Peprotech) were inoculated i.p. into 6-8 weeks-old Zeb1 (+/+) and 
Zeb1 (+/-) mice. The mobilization of monocytes into the peritoneal cavity and their 
maturation into macrophages was followed up at different time points up to 7 h by FACS 
analysis.   
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Endotoxic shock and tolerance susceptibility  
 
Zeb1 (+/+) and Zeb1 (+/-) mice, weighing ~20 g each (6–10 weeks old. A single high 
dose of LPS  (Escherichia coli 055:B5, Sigma-Aldrich), 0.5 mg LPS x 25g mouse was 
used and given i.p. and survival was monitored for 72 h.  For induction of Endotoxin 
Tolerance were used two doses, 1st dose LPS: 100µg LPS x 25g mouse and a 2nd dose 
24 h Later: 200 µg LPS x 25 g mouse. i.p., and survival was monitored for 120 h.  
 
 
 
Isolation and culture of tumor associated macrophages   
 
To generate conditioned medium (CM) from peritoneal macrophages and TAMs, both 
cells types were sorted by flow cytometry and 5 x 105 cells cultured on ultra-low 
attachment 6-well plates (Costar, Corning) during 24 h in 2 ml DMEM supplemented 
with 2% FBS. The CM was then collected and dialyzed overnight against PBS. Wherever 
indicated the CM was concentrated in a high retention dialysis tubing (Sigma-Aldrich) 
with poly-ethylene glycol 20,000 mw (Thermo Fisher Scientific) as per standard 
protocols.  
 
 
 
Chromatin Immunoprecipitation Assays 
 
Chromatin immunoprecipitation (ChIP) assays were performed using EpiQuick ChIP kit 
(Epigentek Group Inc, NY, USA) as per manufacturer’s instructions. Briefly, 1.5 x 107 
bone-marrow derived macrophages were incubated during 10 min with 1% formaldehyde 
solution (Electron Microscopy, PA, USA) at room temperature followed by incubation 
with 1.25 mM glycine. Lysates were sonicated as described elsewhere (Sanchez-Tillo et 
al., 2011). Goat anti-mouse/human ZEB1 (E-20) and its corresponding normal goat IgG 
(Jackson ImmunoResearch) were used. 
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 Identification of DNA binding sequences for ZEB1 and design of primers for qRT-PCR 
was conducted using MacVector software (MacVector Inc, Apex, NC, USA). DNA 
fragments were quantified by qRT-PCR as detailed above using the primers detailed in 
Table 3. In all qRT-PCRs, values shown represent relative binding in relation to input 
and are the average of at least three independent ChIP experiments, each one performed 
in triplicate.  
 
 
 
Table 3. Primers used in qRT-PCR for ChIP assays 
 
 
 
Culture of ID8 cells with conditioned medium, soluble factors, 
drugs and inhibitors 
 
The C57BL/6 mouse ovarian carcinoma cell line ID8 was obtained from K. Roby, 
(University of Kansas, Kansas City, KS, USA) and T. Lawrence (CIML, Marseille, 
France) (Roby et al., 2000) and cultured in complete medium. ID8-GFP cells were 
obtained by stable transfection of ID8 cells with pEGFP-C1 (Clontech Laboratories Inc., 
Mountain View, CA, USA). ID8-luc cells, harboring the luciferase gene obtained from T. 
Lawrence (CIML, Marseille, France) have been previously described (Hagemann et al., 
2008). In selected experiments, 0.5 x 106 ID8-luc cells were plated onto 6-well plates 
with 2 ml of complete medium and supplemented with 100-200 µl of concentrated CM 
from peritoneal macrophages or TAMs during 16-24 h.  
 
 
 
Promoter Region 
 
 
Forward 5’ →  3’ 
 
Reverse 5’ →  3’ 
Ccr2 promoter ZEB1 binding site (-
868 bp &-818bp) (-868/-772 bp) 
CAGGTGCCAATGGA
GTTCAAA 
CCCAAGTTGATTTC
CTATACCC 
Ccr2 promoter Non ZEB1 binding 
sites (NBS) (574/-422 bp) 
 
AGAATGCTTTTGGGT
ACAATGAA 
GTGTAGCATAGGCT
TTATGCTTGG 
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Inhibition of MMP9 in the CM from TAMs was conducted as follows. First, the CM 
from 5 x 105 TAMs isolated from 13-weeks ID8 tumor-bearing Zeb1 (+/+) or Zeb1 (+/-) 
mice was collected and concentrated as detailed above. Then, concentrated CM was 
diluted 30 times in complete medium (30 µl of concentrated CM in 1 ml of complete 
medium) and incubated during 45 min with 20 µM of MMP9 inhibitor dissolved in 
DMSO (MMP-9 PEX Inhibitor 444293, Calbiochem, Millipor, DC, USA) or the 
corresponding volume of DMSO (1 µl of MMP9 inhibitor or DMSO per 1 ml of diluted 
CM). Lastly, 0.3 x 106 ID8-luc cells were plated on 12-wells plates and incubated during 
16 h with 1 ml diluted CM (with or without MMP9 inhibitor) before cells were processed 
for gene expression by qRT-PCR. In experiments using rmMMP9, 0.3 x 106 ID8luc cells 
were plated in 12-wells plates with in 1 ml complete medium supplemented with 1 
mg/ml of rmMMP9 (590502, Biolegend) during 36 hours.  
 
 
Blocking of CCR2 signaling in co-cultures of ID8-luc cells with CM from TAMs was 
carried out as follows. First, six Zeb1 (+/+) and six Zeb1 (+/-) mice were inoculated i.p. 
with 5 x 106 ID8RI cells. After 72 h, mice for each genotype were divided into two 
cohorts and injected i.p. every 12 hours during 3 days with either PBS or 2.5 mg/kg of a 
small molecule CCR2 inhibitor (RS 504393, Tocris) before being sacrificed. The CM 
from TAMs for each mice and cohort were collected as detailed above. The CM was 
diluted twice in complete medium and 1 ml of the diluted CM was added onto ID8-luc 
cells for an additional 72 h before being assessed for Ccl2 expression by qRT-PCR. The 
effect of cisplatin on ID8 cells was examined through two different approaches. In a first 
approach, 5 x 106 ID8-luc were injected in Zeb1 (+/+) and (+/-) mice and allowed to 
grow in these mice for 8 weeks. At this point, (ID8RI) cancer cells were sorted out by 
FACS and 5 x 104 ID8RI cells were plated onto 96-well plates and incubated for 24 h in 
the absence (only complete medium) or presence of 50 µg/ml of cisplatin (Pharmacia 
Nostrum, Madrid, Spain).  
 
 
In the second set of experiments, 5 x 106 ID8-luc were injected in Zeb1 (+/+) and Zeb1 
(+/-) mice and TAMs were then sorted out 96 h after. TAMs were then cultured for 24 h 
as described above to generate CM. 5 x 104 ID8-luc cells were then plated in 96-well 
plate and culture for 24 h in the absence (only complete medium) or presence 50 µg/ml 
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of cisplatin and the CM from Zeb1 (+/+) and Zeb1 (+/-) TAMs.  In both cases, the 
response of ID8 cancer cells to cisplatin was examined through an MTT assay. Briefly, 
15 µl of a 5 mg/ml MTT solution (Sigma-Aldrich) was added to each well for 3 hours at 
37ºC. Then, 100 µl of DMSO was added to each well, incubated for 15 min under dark 
and the absorbance at 590 nm was read with a reference filter 750 in Glomax microplate 
reader (Promega). 
 
 
 
ID8 syngeneic mouse model and bioluminescence imaging 
 
Either 5 × 106 ID8, ID8-GFP or ID8-luc cells were resuspended in 500 µl of PBS and 
injected i.p. into 8 week-old Zeb1 (+/+) and Zeb1 (+/-) female mice. At the indicated 
periods, mice were euthanized and ID8 cells and total macrophages (CD11b+F4/80+) 
were sorted and processed for experimentation. At the end of each protocol, the 
abdominal perimeter, ascites volume and tumor deposits on the peritoneal lining were 
assessed. In selected experiments, tumor progression was followed up over time by 
bioluminescent imaging as described elsewhere (Evans et al., 2014). Briefly, mice were 
injected i.p. with 1.5 mM of CycLuc1 substrate (Calbiochem®, EMD Millipore, 
Billerica, MA, Spain) in 100 µl of PBS. Ten min later mice were anesthetized with 2.5% 
isofluorane and the photon flux signal was collected in a charge-coupled ORCA-2BT 
imaging system (Hamamatsu Photonics, Hamamatsu City, Japan).  
 
 
Bioluminescence data was analyzed with Wasabi! Imaging Software (Hamamatsu 
Photonics) and represented as the total photon flux/sec/cm2 signal emitted from the 
abdominal cavity. In ID8 reinoculation experiments, ID8-luc cells that had been injected 
in Zeb1 (+/+) and Zeb1 (+/-) mice were isolated from the ascites after 13 weeks and re-
inoculated into Zeb1 (+/+) recipients. As ID8RI cells accelerate tumor progression (Cai 
et al., 2015), mice were euthanized 6 weeks post-inoculation and peritoneal cells were 
isolated for subsequent analysis. 
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Adoptive transfer of bone marrow-derived macrophages into 
mice tumor-bearing mice 
 
Adoptive transfer of macrophages into ID8 tumor-bearing mice was performed as in 
(Hageman et al., 2008). Female Zeb1 (+/+) mice were injected with 1 x 106 ID8RI-luc 
cells previously inoculated in Zeb1 (+/+) female mice during 13 weeks. Twenty-three 
days after re-inoculation of ID8RI-luc cells, mice were inoculated with 3-4 x 106 BMDM 
from Zeb1 (+/+) and Zeb1 (+/-) mice. Tumor progression was monitored by 
bioluminescence imaging as described above. Mice were euthanized 7 days after BMDM 
inoculation and peritoneal cells were isolated for subsequent analysis. 
 
 
 
Human samples  
 
For correlations between relevant protein expression, a series of 18 cases of different 
stages of serous ovarian carcinomas were obtained from the Hospital Clinico San Carlos 
(Madrid, Spain). In case of survival plots correlating ZEB1 expression in TAMs and 
ovarian carcinoma patients survival, 18 cases of grade III and IV with complete surgery 
were obtained from the Hospital Clinico San Carlos (Madrid, Spain).  Use of human 
samples was approved by the corresponding local Ethics Research Committees. 
 
 
 
Immunohistochemistry of human ovarian carcinomas 
 
Immunohistochemistry of formalin-fixed, paraffin-embedded human samples of a series 
of 35 cases of human ovarian carcinomas was carried out as follows. Slides were 
deparaffinized and rehydrated before being subjected to antigen retrieval with 10 mM 
sodium citrate pH 6.0 for 5 min. Slides were then incubated with a non-specific binding 
blocking solution (5% donkey/goat normal serum plus 4% BSA in PBS, 0.5% Tween 20) 
followed by the corresponding primary and HRP-conjugated secondary antibodies (see 
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above for the source of antibodies). Staining was performed mannually except for CD163 
that was performed automatically in a Bond-Max automatic stainer (Leica Biosystems, 
clone 10D6).  
 
 
The primary antibodies used were as follows: ZEB1: 1/250 dilution overnight at 4ºC; 
CCL2: 1/50 dilution overnight at 4ºC; CCR2: 1/100 dilution overnight at 37ºC; MMP9: 
1/50 dilution overnight at room temperature; and CD163: 1/3000 dilution 1 h at room 
temperature. Secondary antibodies were incubated at 1/100 during 1 h at 37ºC, except for 
ZEB1 (1/200, 1 h at 37ºC) and CD163 (1/200, 30 min at room temperature). For CD163, 
automated staining was conducted as follows. Antigen retrieval was carried out with low 
pH Bond ER2 Buffer Solution® (Vision Biosystems, Leica, Wetzlar, Germany) for 30 
min, followed by incubations with CD163 antibody (30 min, room temperature) and 
Bond Refine Polymer (Vision Biosystems) (20 min, room temperature). The 
immunohistochemistry reaction was developed with a DAB substrate kit (Vector Labs, 
Burlingame, CA) before slides were counterstained with hematoxylin and mounted in 
Di-N- butylPhthalate in Xylene solution (DPX, Sigma-Aldrich).  
 
 
The number of positive cells was scored by microscopic analysis at 400X magnification. 
Statistical analyses of immunohistochemistry data was as follows. The percentage of 
tumor cells and TAMs expressing each protein was determined and cases were then 
segregated by their expression of ZEB1—in tumor cells or in TAMs—below or above 
the median. The means for CCL2 expression in tumor cells (n = 18), the percentage of 
TAM infiltration—determined by expression of CD163—(n = 18), and the expression of 
CCR2 (n = 15) and MMP9 (n =15) in TAMs was calculated for the low and high ZEB1 
cohorts and the significance of their difference was assessed by a Mann-Whitney U test. 
Correlations between relevant protein expression pairs in tumor cells and/or TAMs in 
serious ovarian carcinomas (n = 15) were assessed by a Spearman’s correlation 
coefficient (r). Their significance is represented by the p value.  
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Survival plots of women ovarian cancer patients  
 
Correlation between the expression of ZEB1 and CCL2 and progression-free survival was 
examined in published array databases of ovarian carcinoma. Only datasets publishing 
survival data with a mean follow-up of at least 2 years and using the Affymetrix Human 
Genome chips were considered to avoid platform differences when using different gene 
arrays. After MAS5 normalization in the R statistical environment, the probe set 
212758_s_at was used for ZEB1 and the probe set 216598_s_at was used for CCL2. The 
four datasets included in the study are GSE15622 (Ahmed et al., 2007), GSE26193 
(Mateescu et al. 2011), GSE30161 (Ferriss et al., 2012), and GSE26712 (Bonome et al., 
2008). Datasets were processed separately and assembled into a single final database. 
Cox proportional hazards regression analysis was performed and Kaplan-Meier survival 
plot was generated to compare survival of patients displaying high and low expression of 
the genes in the R statistical environment as described previously (Mihály et al., 2013).  
 
 
 
Statistical analysis 
 
Statistical analysis of all the data in this dissertation was performed using Prism for Mac 
version 5.0a (GraphPad Software Inc., La Jolla, CA, USA). Statistical significance was 
assessed with a non-parametric Mann-Whitney U test except in Kaplan Meier survival 
plots of ovarian cancer patients where a Cox proportional hazard regression was used. 
Error bars in all figures represent standard errors of means. Histogram bars represent the 
means with standard errors and relevant comparisons of conditions were labeled as either 
significant at the p ≤ 0.001 (***), p ≤ 0.01 (**) or p ≤ 0.05 (*) levels, or non-significant 
(ns) for values of p > 0.05.  
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Chapter I :  Role of ZEB1 in macrophage 
differentiation and polarization 
 
 
 
1. Zeb1 expression and function during monocyte-
macrophage differentiation  
  
 
As ZEB1 inhibits the terminal differentiation, I first examined the expression of Zeb1 
during monocyte-to-macrophage differentiation in mouse. Then, wild-type C57BL/6 
mice were treated with M-CSF and the mRNA expression of Zeb1 was examined in bone 
marrow total cells (BMTCs) and in mononuclear myeloid cells in the peritoneal cavity, 
an easily accessible source of macrophages (Zhang et al., 2008). I found that expression 
of Zeb1 was higher in monocytes (CD11b+F4/80-) than in macrophages (CD11b+F4/80+) 
(Figure 4).  
 
 
As noted earlier, expression of F4/80 antigen distinguishes those macrophages that 
originated from peripheral blood monocytes (CD11b+F4/80low macrophages) from those 
that have differentiated from embryonic precursors (CD11b+F4/80high macrophages). 
Peritoneal CD11b+F4/80high  macrophages are larger in size—and referred as large 
peritoneal macrophages (LPM)—and represent the largest fraction in basal conditions but 
disappear upon bacterial lipopolysaccharide (LPS) or thioglycolate (TG) stimulation. In 
turn, CD11b+4/80low are smaller—and consequently referred as small peritoneal 
macrophages (SPM)—express high levels of MHCII and are the main population 
following LPS or TG stimulation that increases monocyte migration and macrophage 
yields. LPM and SPM also differ in the functionally, LPM exhibit greater phagocytic 
activity than SPM (Goshn et al 2010; Rei et al 2014). As shown in Figure 4, Zeb1 was 
almost exclusively expressed in CD11b+F4/80low SPM.  
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Figure 4. Wild-type C57BL/6 mice were injected i.p. with M-CSF and 4 h later bone marrow total cells 
(BMTC) and peritoneal cells were harvested and, in the case of peritoneal cells, sorted for CD11b and 
F4/80. Zeb1 relative mRNA expression with respect to Gapdh was then assessed in BMTC, peritoneal 
monocytes (CD11b+F4/80), small peritoneal macrophages (SPMs, CD11b+F4/80low) and large peritoneal 
macrophages (LPMs, CD11b+F4/80high) by quantitative real time PCR (qRT-PCR).  
 
 
 
Next, I characterized Zeb1 expression and function in macrophages under homeostatic, 
since they begin to develop from bone marrow pluripotent cell until to reach macrophage 
state. Using mice with heterozygous deletion of Zeb1 [Zeb1 (+/-)]—null Zeb1 (-/-) are 
embryonic lethal— I characterized Zeb1 expression and function in macrophages under 
homeostatic and activation conditions, since they begin to develop from bone marrow 
pluripotent cell until to reach mature macrophage state. Bone marrow cells treated in 
vitro with either GM-CSF or M-CSF render cells with a gene expression profile closer to 
macrophages than to dendritic cells but the former generates cells secreting more 
inflammatory cytokines and less anti-inflammatory cytokines (M1-like macrophages) 
than the later (Fleetwood et al., 2007; Lacey et al., 2008). Bone marrow myeloid cells 
from wild type Zeb1 (+/+) and heterozygous Zeb1 (+/-) mice were derived into 
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macrophages by incubation with GM-CSF or M-CSF. As shown in Figure 5, expression 
of CD11b and F4/80 was similar in Zeb1 (+/+) and Zeb1 (+/-) bone marrow-derived 
macrophages suggesting that Zeb1 is dispensable for precursor myeloid cells 
differentiation into macrophages.        
  
 
 
                  
 
Figure 5. Bone marrow total cells (BMTCs) from Zeb1 (+/+) and Zeb1 (+/-) mice were derived into 
macrophages by incubation with GM-CSF or M-CSF as described in Materials and Methods and the 
distribution of macrophage subpopulations determined by CD11b and F4/80 expression by FACS.  
 
 
 
I also investigated whether Zeb1 plays a role in peritoneal macrophage homeostasis. I 
found that the number of macrophages, as the percentage of CD11b+F4/80+ cells in the 
peritoneal exudate, was significantly higher in Zeb1 (+/-) mice than in Zeb1 (+/+) mice. 
Zeb1
(+/+)
Zeb1 
(+/-)
CD
11
b
F4/80 F4/80
CD
11
b
M-CSF
CD
11
b
CD
11
b
F4/80 F4/80
GM-CSF
	 56	
At the same time, the ratio F4/80high vis-à-vis F4/80low macrophages was significantly 
larger in Zeb1 (+/-) mice (Figures 6, 7 and 8). Thus, Zeb1 modulates the total number of 
macrophages and the ratio of F4/80high and F4/80low macrophages populations as Zeb1 
deficient mice have higher levels of F4/80high. 	
                                                                                    
Figure 6. Six animals for each genotype Zeb1 (+/+) and Zeb1 (+/-) mice were analyzed for the percentage 
of macrophages (CD11b+F4/80+) out total peritoneal exudate cells  
 
 
 
                                                  
 
Figure 7. Peritoneal macrophages from Zeb1 (+/+) and Zeb1 (+/-) mice were examined by FACS for 
CD11b and F4/80 expression. Graphic shows F4/80high to F4/80low ratio values are means with standard 
errors of six mice for each genotype. 
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 Figure 8. A representative plot for each genotype is shown. Gates numbering corresponds to total 
macrophages (1), SPMs (2) and LPMs (3).  
 
 
 
 
 
 
2. Zeb1 modulates genes related to inflammation and 
SPM subpopulation 
 
 
 The results above indicated that ZEB1 is dispensable for the development of 
macrophages but, in turn, it modulates the distribution of subpopulations of 
macrophages, which differ in ontogeny, polarization profile and function. Consequently, 
I evaluated whether Zeb1 has a role in macrophage polarization profile. First I 
characterized this activation state through their gene related polarization expression in 
both subpopulations in macrophages from wild-type mice. As expected, SPM and LPM 
subpopulations present different activation profile. LPMs have a reduced expression of 
several pro-inflammatory markers compared to SPM that have a pro and anti-
inflammatory mixed phenotype (Figure 9).  
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Figure 9. Gene expression of Ccr2, Mrc1 and Il1b in LPM and SPM subpopulations from three wild-type 
mice was analyzed by qRT-PCR. 
 
 
 
 
I then next investigated whether Zeb1 expression regulates the expression of these and 
other genes associated to either classical or alternative activation in macrophages in wild 
type peritoneal macrophages where Zeb1 expression had been knockdown by siRNA. 
Zeb1 (+/+) peritoneal macrophages were transfected with either a siRNA control (siCtl) 
or siRNA against Zeb1 (siZeb1), which specificity has been previously shown (Siles et 
al., 2013). The expression of M2- and/or TAM-associated genes as Ccr2, Cxcl15, Cd163, 
Mrc1 and Retnla were lower in Zeb1 knocked down macrophages than in macrophages 
transfected with siCtl. Conversely, expression of the M1-associated gene Socs3 was 
higher in macrophages interfered with siZeb1 than in those transfected with siCtl (Figure 
10).   
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Figure 10.  Gene expression analysis in wild-type and Zeb1-deficient peritoneal macrophages interfered 
with a specific siRNA against mouse Zeb1 (siZeb1) or a siRNA control (siCtl). Data represent at least three 
independent experiments.  
 
 
 
Zeb1 was also interfered with siZeb1 in mouse bone marrow cells. As shown in Figure 
11 expression of Cd163 and Wnt5a is also downregulated. It is known the association of 
Wnt5a overexpression with tumor aggressiveness. Wnt5a is produced by monocytes and 
monocyte-derived macrophages and regulates VEGF-C production and macrophage 
immunotolerant phenotype (Sessa et al., 2016).  
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Figure 11. Expression of Zeb1, Wnt5a and Cd163 in bone marrow total cells (BMTCs) interfered with 
siCtl or siZeb1.was assessed by qRT-PCR for the expression of Wnt5a and Cd163, along with ZEB1 as 
control, with reference to Gapdh. 
 
 
 
 
 
I also examined if the role of ZEB1 in human macrophages is parallel that I found in 
mouse counterparts. Human CD14+ peripheral blood monocytes were treated with either 
M-CSF (CSF1) or GM-CSF (CSF2) to generate macrophages that were then interfered 
with either a siCtl or a siRNA against human ZEB1 (siZEB1) (Sanchez-Tillo et al., 
2011). As shown in Figure 12, ZEB1 interference also resulted in the downregulation of 
CD163 and WNT5A. Altogether, the results above indicated that ZEB1 activates the 
expression of genes in macrophages associated to their activation. 
 
 
 
 
 
 
Re
lat
ive
 m
RN
A 
ex
pr
es
sio
n
0
40
80
120
Wnt5a
**	
Zeb1
**	
Cd163
*	
siCtl
siZeb1
	 61	
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Figure 12. Human macrophages derived from peripheral blood CD14+ monocytes treated with either 
recombinant human M-CSF (CSF1) or GM-CSF (CSF2) and interfered with a specific siRNA against 
human ZEB1 (siZEB1) or a siRNA control (siCtl) and were assessed by qRT-PCR for the expression of 
WNT5A and CD163, along with ZEB1 as control, with reference to GAPDH. Data show two independent 
experiments. 
 
 
 
Lastly, I also analyzed if Zeb1 activates genes that are associated to inflammation in 
peritoneal macrophages from Zeb1 (+/+) and Zeb1 (+/-) mice. In line with my results 
above, compared to their wild-type counterparts, peritoneal macrophages from Zeb1 (+/-) 
mice expressed reduced mRNA levels of a number of both pro-inflammatory and anti-
inflammatory genes. Thus, Zeb1 (+/-) macrophages expressed lower levels of Ccr2, 
Nfkβ1, Il1β, Cxcl15/Il8, Il10, Cd163, Cd206/Mrc1, Retnla and Mmp9, on the other hand, 
expression of Gata6 which expression is associated to LPMs was higher in Zeb1 (+/-) 
macrophages (Figure 13). Interestingly, all of these genes are related with SPM 
subpopulation. Therefore, Zeb1 not only modulates the distribution of LPM and SPM 
populations and increases the latter, but it also activates SPM-associated genes.   	
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Figure 13. Peritoneal macrophages from 6-8 week-old Zeb1 (+/+) and Zeb1 (+/-) mice, four mice for each 
genotype, were assessed for the indicated genes with respect to Gapdh by qRT-PCR.  
 
 
 
3. Gene expression analysis using RNA-Sequencing data 
 
 
I decided to study the gene signature associated to Zeb1 in peritoneal macrophages. To 
that effect, RNA transcripts from Zeb1 (+/+) and Zeb1 (+/-) peritoneal macrophages were 
compared by RNAseq technology that was performed at the Centro Nacional de Análisis 
Genómico (Barcelona). The gene signature in the three samples for each condition was 
very similar as shown in the MDS plot (Figure 14).  
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Figure 14. Multidimensional scaling (MDS) plot of digital gene expression profiles for the RNAseq data 
obtained from mRNA libraries of peritoneal macrophages from Zeb1 (+/+) (black) and Zeb1 (+/-) (red) 
mice. MDS plot show the relations between the samples in two dimensions and distances on the plot 
represent the biological coefficient of variation of expression between samples.  
 
 
 
 
 
For all samples, hierarchical clustering was performed using Genesis software as shown 
in Figure 15 normalizing rows of data for similar distribution.  Samples could be 
separated in 2 groups according their genotype, where Zeb1 (+/-) samples form A and 
Zeb1 (+/+) samples form B group. Of the 12,877 genes that yielded the RNAseq, 412 
were significantly differentiantly expressed (DE) between both groups. Genes were 
grouped in order their correlation in six clusters.  
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Figure 15. Hierarchical clustering of 412 differentially expressed genes in peritoneal macrophages from 
Zeb1 (+/+) and Zeb1 (+/-) mice. Each row represents a gene and each column a sample. The color scale 
ranges from saturated red for upregulated genes to green for downregulated genes. 
 
 
 
 
A Gene Ontology (GO) and an enriched KEGG pathways functional analysis of DE 
genes were performed. These bioinformatics analyses revealed that most DE genes were 
associated to immune system processes and hematopoietic cell lineage functions  (Tables 
4 and 5).  
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Biological Process 
 
 
Cou
nt 
 
% 
 
p value 
 
GO:0002376 immune system process 34 6,60 6,21E-10 
GO:0006954 inflammatory response 25 4,85 8,52E-06 
GO:0019886 antigen processing and presentation of 
exogenous peptide antigen via MHC class II 
6 1,16 1,60E-05 
GO:0001816 cytokine production 7 1,36 2,82E-05 
GO:0007155 cell adhesion 29 5,63 3,92E-05 
GO:0006874 cellular calcium ion homeostasis 12 2,33 4,11E-05 
GO:0019882 antigen processing and presentation 8 1,55 3,78E-04 
GO:0050853 B cell receptor signaling pathway 8 1,55 4,24E-04 
GO:0031623 receptor internalization 7 1,36 4,45E-04 
GO:0002250 adaptive immune response 12 2,33 6,73E-04 
GO:0042113 B cell activation 6 1,16 6,96E-04 
GO:0007568 aging 14 2,71 7,67E-04 
GO:0000082 G1/S transition of mitotic cell cycle 8 1,55 8,84E-04 
GO:0006164 purine nucleotide biosynthetic process 5 0,97 0,001115 
GO:0002504 antigen processing and presentation of 
peptide or polysaccharide antigen via MHC class II 
4 0,77 0,001171 
GO:0006955 immune response 19 3,69 0,001241 
GO:0009615 response to virus 9 1,74 0,001298 
GO:0007399 nervous system development 21 4,07 0,001345 
GO:0031589 cell-substrate adhesion 5 0,97 0,001367 
GO:0034113 heterotypic cell-cell adhesion 5 0,97 0,001367 
GO:0016337 single organismal cell-cell adhesion 10 1,94 0,001673 
GO:0007157 heterophilic cell-cell adhesion via 
plasma membrane cell adhesion molecules 
7 1,35 0,001833 
GO:0021785 branchiomotor neuron axon guidance 4 0,78 0,002216 
GO:0030335 positive regulation of cell migration 14 2,72 0,002217 
GO:0010628 positive regulation of gene expression 21 4,08 0,002836 
GO:0006816 calcium ion transport 11 2,13 0,002937 
GO:0071353 cellular response to interleukin-4 5 0,97 0,003234 
GO:0035556 intracellular signal transduction 21 4,08 0,003261 
GO:0007166 cell surface receptor signaling pathway 14 2,72 0,003601 
GO:1902287 semaphorin-plexin signaling pathway 
involved in axon guidance 
4 0,78 0,003701 
 
Table 4. Gene Ontology (GO) functional enrichment of genes differentially expressed (DE) between Zeb1 
(+/+) and Zeb1 (+/-) peritoneal macrophages. Only the top 30 biological process with value p<0.05 are 
shown. The first column refers to the GO term and the description of the biological process. The second 
and third columns indicate the number of genes and the share (in percentage) out all genes, respectively. 
The fourth column shows the p value 
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Biological Process 
 
 
Cou
nt 
 
% 
 
p value 
 
mmu04514: Cell adhesion molecules (CAMs) 18 3,74 6,11E-06 
mmu04640: Hematopoietic cell lineage 12 2,49 5,97E-05 
mmu03010: Ribosome 12 2,49 1,02E-04 
mmu05416: Viral myocarditis 11 2,28 7,22E-04 
mmu04662: B cell receptor signaling pathway 10 2,07 8,87E-04 
mmu04672: Intestinal immune network for IgA  7 1,45 0,006840 
mmu00562: Inositol phosphate metabolism 7 1,45 0,006840 
mmu04070: Phosphatidylinositol signaling system 8 1,66 0,009271 
mmu04510: Focal adhesion 14 2,91 0,009809 
mmu03320: PPAR signaling pathway 8 1,66 0,012185 
mmu05310: Asthma 5 1,03 0,019538 
mmu04612: Antigen processing and presentation 8 1,66 0,024827 
mmu05200: Pathways in cancer 18 3,74 0,026591 
mmu04650: Natural killer cell mediated cytotoxicity 9 1,87 0,039307 
mmu04512: ECM-receptor interaction 7 1,45 0,047312 
 
 
 
Table 5. Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis of genes differentially expressed 
(DE) between Zeb1 (+/+) and Zeb1 (+/-) peritoneal macrophages. The first column refers to the KEGG 
term and the description of the biological process. The second and third columns indicate the number of 
genes and the share (in percentage) out all genes, respectively. The fourth column shows the p value.  
 
 
Interestingly, many of the DE genes are implicated in macrophage activation/polarization 
and/or are associated to F4/80high and F4/80low phenotypes (e.g. Cd163, Mrc1, Retnla), 
corroborating my findings above about a potential role of Zeb1 in macrophage activation 
(Figure 16).  
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Figure 16.  Hierarchical clustering of some of top DE genes up and downregulated.  
 
 
 
 
Use of the GENEMANIA platform allowed me to elaborate a network weighting for 
some DE genes of the RNA-seq. Figure 17 shows the network established by the 
coexpression of Mrc1, Ccr2, Mmp9, Cd163 and Retnla. It is interesting to note that other 
TAM-related genes as Csf1, Il10 and Nfkb are coexpressed with the DE genes obtained in 
the RNAseq,  
 
 
 
 
 
 
 
 
 
 
      
 
 
Figure 17. Gene network extracted from GENEMANIA, describing the genetic relation for some 
inflammatory DE genes from RNA-seq. The arrows in purple represent co-expression of determined genes. 
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4. Socs3 is involved in Zeb1 regulation 
 
 
 
All of these data indicate that Zeb1 regulates macrophage phenotype and SPM 
distribution, and both anti and pro-inflammatory markers. This led me to explore other 
mouse models involved in the activation and distribution of peritoneal macrophages, 
including genes with could have common pathways with Zeb1 and study how it is 
modulating macrophage activation and try to revert Zeb1 deficiency through an in vivo 
model. Therefore, I used mice deficient for either Socs2 or Socs3 genes.  
 
 
 
In order to inquire whether Zeb1 regulates macrophage polarization through cross-
regulation of Socs2 or Socs3 and if macrophage polarization is restored or enhanced, I 
crossed Socs2 (-/-) and Socs3Lyz2cre/Zeb1 (+/+) with Zeb1 (+/-) mice. I analyzed the 
peritoneal exudate from these different mice and examined changes in macrophage 
distribution by FACS. I did not observe clear differences in peritoneal macrophage 
subpopulations between Socs3Lyz2cre/Zeb1 (+/+) and Socs3Lyz2cre/Zeb1 (+/-) mice (Figure 
18).  
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Figure 18. Flow cytometric dot plot of cells to peritoneal lavage cells from Zeb1 (+/+), Socs3Lyz2cre/Zeb1 
(+/+), Socs3Lyz2cre/Zeb1 (+/-), and Zeb1 (+/-) mice. There are variations in F4/80high and F4/80low 
populations as is known in these mice, but there is not difference between Socs3Lyz2cre/Zeb1 (+/+) 
Socs3Lyz2cre/Zeb1 (+/-) mice. 
 
 
 
Next, I analyzed the expression of Zeb1 and other polarization-associated genes in 
peritoneal macrophages from these mice and found a similar patron in gene expression in 
macrophages from Socs3Lyz2cre/Zeb1 (+/+) and Socs3Lyz2cre/Zeb1 (+/-) mice (Figure 19). 
Based on the gene expression profile, I concluded that Socs2 did not alter the 
polarization, nor have direct relationship with Zeb1. 
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Figure 19. Gene expression analysis by qRT-PCR (relative to Gapdh mRNA levels) in peritoneal 
macrophage from Zeb1 (+/+) (WT), Socs2-/- (SOCS2) Socs2-/-Zeb1(+/-) (SOCS2 Zeb1) Socs3Lyz2cre (SOCS3) 
Socs3Lyz2cre/Zeb1 (+/-) (SOCS3 Zeb1) and Zeb1 (+/-) (Zeb1) mice. 
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Surprisingly, Socs3Lyz2cre/Zeb1 (+/+) mice express non-detectable mRNA or protein 
levels of Zeb1 (Figures 19, 20 and 21). In addition, I found that Socs3 expression was 
upregulated in Zeb1 (+/-). Likewise, classical ZEB1 target genes in epithelial tissues, like 
E-cadherin, were overexpressed in Socs3Lyz2cre/Zeb1 (+/+) mice (Figure 20). These results 
indicated that Zeb1 and Socs3 modulate each other expression in peritoneal macrophages. 
 
 
  
 
 
Figure 20. Gene expression analysis by qRT-PCR (relative to Gapdh mRNA levels) in peritoneal 
macrophage from different mice. Histogram show average of two independent experiments. 
 
 
 
 
 
 
 
 
                          
 
 
    
 
 
Figure 21.  Western blot for ZEB1 protein expression. β-Actin was used as a control.  
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Next, I sought to investigate the molecular mechanism of this mutual regulation between 
Zeb1 and Socs3. To that effect, Zeb1 was overexpressed in peritoneal macrophage using 
lentivirus that carries the mouse Zeb1 gene fused to GFP. Transduced cells were 
analyzed for Zeb1 expression and GFP. Peritoneal macrophages showed high 
transduction efficiencies as scored by FACS with over  >50% of cells positive for GFP 
(Figure 22). These transduced cells I assessed by qRT-PCR for the expression of 
different genes associated to polarization as well as Zeb1 and Socs3 target genes. Genes 
like Ccr2 displayed a similar expression pattern in normal macrophages and in 
Socs3f/fLyz2cre+/- macrophages when overexpressed Zeb1. In both situations levels were 
higher when Zeb1 was overexpressed, independently of Socs3 levels. Nevertheless, other 
genes like Gata6 or Il6 displayed different regulation as shown in Figure 23. These data 
indicate that some genes are regulated for Socs3 in independently of Zeb1.   
 
 
                  
 
 
 
Figure 22. FACS dotplot and histogram showing peritoneal macrophages from Zeb1 (+/+) (n=2) and 
Socs3Lyz2cre (n=2) mice transduced with a lentiviral Zeb1 expression vector co-expressing eGFP, or a 
control vector expressing eGFP only are shown. 
            
 
 
GFP+ 
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Figure 23. mRNA expression levels for Zeb1 and other Zeb1 and Socs3-related genes with respect to 
Gapdh  were analyzed by qRT-PCR 96 h after transduction. Data show two independent experiments. 
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Chapter II :  Role of ZEB1 in macrophage 
function 
 
 
 
 
1. Zeb1 expression impairs macrophage phagocytosis 
 
 
Macrophages are specialized phagocytes that remove pathogens and clear dead and 
malignant cells. CD11b+F4/80high LPMs display higher phagocytic capacity than 
CD11b+F4/80low SPMs (Cain et al., 2013). Since my results above indicate that Zeb1 (+/-
) mice have a larger CD11b+F4/80high LPM subpopulation, I studied the phagocytic 
capacity of peritoneal Zeb1 (+/+) and Zeb1 (+/-) macrophages. To that effect, I used the 
ID8 syngeneic murine ovarian cancer model. Intraperitoneal (i.p.) injection of ID8 cancer 
cells results in their rapid growth and development of ascites with abundant infiltration of 
immune cells, mostly TAMs (Hagemann et al., 2006; Hagemann et al., 2008).  
 
 
I stably transfected ID8 cells with an expression vector encoding GFP and injected them 
or ID8 CFSE-labeled i.p. into Zeb1 (+/+) and Zeb1 (+/-) mice. The peritoneal exudate 
was harvested after 3 h and phagocytosis of ID8-GFP cells by F4/80 macrophages was 
assessed by FACS. I found that peritoneal macrophages from Zeb1 (+/-) displayed higher 
phagocytic capacity than their Zeb1 (+/+) counterparts (Figure 24).  
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Figure 24. Upper panel: Zeb1 (+/-) macrophages display increased phagocytic capacity. Zeb1 (+/+) and 
Zeb1 (+/-) mice were injected i.p. with ID8-GFP cells and 3 h later mice were euthanized and in vivo 
phagocytosis was assessed by FACS as F4/80+ cells that were also GFP+ (gate 1). Lower panel: The 
histogram shows the percentage of ID8 cells phagocyted in relation to the total peritoneal cells. 
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2.  ZEB1 expression promotes macrophage migration 
 
ZEB1 enhances the invasive behavior in cancer cells. Consequently, I sought to 
investigate whether Zeb1 also regulates migration in macrophages. First, I analyzed the 
basal motility of Zeb1 (+/+) and Zeb1 (+/-) peritoneal macrophages in an in vitro wound 
healing assay. In the absence of chemotactic stimuli, Zeb1-deficient macrophages 
showed a slower closure of the scratch wound than wild-type macrophages (Figure 25).  
 
 
 
 
                        
 
Figure 25. Zeb1 (+/+) peritoneal macrophages migrated more than Zeb1 (+/-) ones in a wound healing 
assay. Images shown are representative of at least four different mice for each genotype.  
 
 
 
In addition to its role in the recruitment of circulating monocytes into the tumor 
microenvironment, CCL2 is required for the mobilization of pro-inflammatory CCR2+ 
monocytes into inflammatory and infection foci (Serbina and Palmer, 2006; Si et al., 
2010). I examined the chemotaxis of macrophages from both genotypes to CCL2 in a 
Transwell® migration assay and found that Zeb1 (+/-) macrophages migrated less 
efficiently to mouse recombinant Ccl2 (mrCcl2) than their wild-type counterparts (Figure 
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26). These data indicate that Zeb1 promotes macrophage motility both under basal and 
chemotactic conditions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Transwell® chemotaxis assay for CFSE-labeled peritoneal macrophages from Zeb1 (+/+) and 
Zeb1 (+/-) mice under the stimulus of recombinant mouse Ccl2. Values are the means of relative 
fluorescence units (RFU) of five mice for each genotype with standard errors.  
      
 
 
The lower migratory capacity of Zeb1 (+/-) macrophages was then assessed in vivo by 
examining the adoptive transfer of BMTC and BMDM into wild-type mice. BMTC and 
BMDM from Zeb1 (+/+) and Zeb1 (+/-) mice were labeled with the fluorescent cell 
tracer carboxyfluorescein succinimidyl ester (CFSE) and injected intravenously (i.v.) in 
Zeb1 (+/+) mice. A control cohort of Zeb1 (+/+) mice was injected with PBS. In the case 
of BMTCs mice received a thyoglicolate i.p. injection after BMTCs i.v. injection and  
peritoneal exudates were collected and analyzed for CFSE+ cells 72 hours after, and for 
BMDM peritoneal exudate was analyzed 24-48 hours after inoculation. In line with my 
ex vivo results above, BMDMs and BMTCs from Zeb1 (+/+) migrate more efficiently 
than their Zeb1 (+/-) counterparts (Figures 27 and 28). 
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Figures 27 and 28. Increased in vivo migration of Zeb1 (+/-) BMTCs and BMDMs in adoptive transfer 
assays. CFSE-labeled BMTCs and BMDMs from Zeb1 (+/+) and Zeb1 (+/-) mice were inoculated into 
Zeb1 (+/+) mice and their BMTC/BMDM in vivo migration into the peritoneal cavity was examined 24-72 
h later as described in Materials and Methods. 
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3. Zeb1 expression impairs macrophage maturation to LPM 
subpopulation 		
I next explored whether Zeb1 regulates bone marrow mobilization of monocytes in vivo 
by chemotactic stimuli such as M-CSF, CCL2 or by ID8 tumor cells. Intraperitoneal 
injection of M-CSF or CCL2 in Zeb1 (+/-) mice failed to elicit the mobilization and 
peritoneal infiltration of monocytes and the reduction in LPMs that is observed in Zeb1 
(+/+) mice after only 3 h (Figures 29 and 30), the same phenomena occurs using ID8 
tumor cells as chemotactic stimulus after 72 hours (Figure 29).  
 
 
 
 
 
Figure 29. Zeb1 (+/+) and Zeb1 (+/-) mice were injected i.p. with PBS, CSF1, CCL2 for 3 hours or ID8 
cells for 72 hours, and cells were analyzed by FACS 
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Figure 30. Four Zeb1 (+/+) and four Zeb1 (+/-) mice were injected i.p. with PBS or CSF1 and monocyte 
chemotaxis into the peritoneum and maturation into macrophages was examined after 3 h. 
 
 
 
 
After 7 hours, SPM and LPM subpopulations almost recovered to basal conditions in 
Zeb1 (+/+) but not in Zeb1 (+/-) mice (Figure 31). Altogether, these results indicate a 
deficient mobilization of monocytes-macrophages in Zeb1 (+/-) mice.   
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Figure 31.  Zeb1 (+/+) and Zeb1 (+/-) mice were treated with CSF1 and the peritoneal myeloid 
subpopulation assessed by FACS as in Figure 22 over time (20 min-7h). 
 
 
 
 
Next, I investigated whether the wild-type or Zeb1-deficient microenvironment 
background influences the migration of monocytes into the peritoneal cavity and their 
subsequent maturation into macrophages. To that effect, BMTCs from Zeb1 (+/+) and 
Zeb1 (+/-) mice were labeled with CFSE and injected i.v. and M-CSF i.p. into a Zeb1 
(+/+) recipient background. After only 4 h, a larger share of Zeb1 (+/-) BMTCs [BMTC 
(+/-)] than wild-type ones [BMTC (+/+)] had differentiated toward macrophages (Figure 
32). At later times (7 h), virtually all macrophages originated from BMTC (+/-), but only 
a small fraction of those originated from BMTC (+/+), were F4/80high LPMs.  
 
 
 
Altogether, these results indicate that BMTC (+/-) differentiate into macrophages more 
efficiently than wild type BMTCs and that Zeb1 blocks monocyte-to-macrophage 
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differentiation. In addition, these results allow me to conclude that the failure of BMTC 
(+/-) to generate F4/80low SPMs is independent of the microenvironment background of 
the recipient host—whether Zeb1 (+/-) or (+/+)—but it is rather intrinsic to the Zeb1-
deficiency of BMTCs. 
 
 
 
 
                             
 
Figure 32. CFSE-labeled BMTCs from Zeb1 (+/+) (BMTC (+/+)) and Zeb1 (+/-) (BMTC (+/-)) mice were 
inoculated into wild-type mice. Mice were then injected i.p. with CSF1 and myeloid cell mobilization was 
assessed at 3 h and 7 h.  
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4. Zeb1 in response to LPS-induced endotoxic shock and 
tolerance 
 
 
In light of the results above indicating that Zeb1 regulates key pro-inflammatory and 
anti-inflammatory genes, I examined whether Zeb1 modulates LPS-induced endotoxic 
shock and tolerance responses. Injection of LPS into mice triggers a strong pro-
inflammatory macrophage-induced and NFκB-mediated response with high secretion of 
Tnfa, Il1β, Il6, and Cox2, which could eventually lead to death (Benoit et al., 
2008). However, when mice are subjected to repeated doses of LPS, they developed a 
protective adaptive response (endotoxin tolerance) characterized by the inability of 
macrophages to produce pro-inflammatory cytokines and their switch to an anti-
inflammatory phenotype (Il10, Tgfβ1, Il1ra) (Biswas and Lopez-Collazo, 2009; Pena et 
al., 2011). Since my results above indicate that Zeb1 regulates key pro-inflammatory and 
anti-inflammatory genes, I examined whether Zeb1 modulates LPS-induced endotoxic 
shock and tolerance responses.  
  
 
Zeb1 (+/+) and Zeb1 (+/-) mice were injected i.p. with a single lethal dose of LPS and 
their survival followed over time. I found that Zeb1-deficient mice have improved 
survival rates to LPS-induced shock compared than Zeb1 (+/+) mice (Figure 33). This is 
in line with Figure 13 showing that Zeb1 (+/-) macrophages produce lower levels of Il1b, 
Nfkb1/p50 and Il8.  
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Figure 33. Kaplan Meier survival plots of Zeb1 (+/+) and Zeb1 (+/-) mice treated with a single lethal dose 
of LPS (endotoxic shock).  
 
 
 
 
 
 
Next, mice from both genotypes were injected with a single sub-lethal dose of LPS 
followed by a lethal dose of LPS. Under these conditions, the opposite pattern was 
observed; Zeb1 (+/-) mice died throughout the protocol, while all Zeb1 (+/+) mice 
survived, indicating that Zeb1 conferred strong protection against secondary endotoxin 
re-challenge (Figure 34). These data are also consistent with Figure 13, where Zeb1 (+/-) 
macrophages failed to shift to an anti-inflammatory state and displayed lower levels of 
Il10. Altogether, these results indicate that Zeb1 enhances not only the in vivo 
inflammatory response to LPS-induced endotoxic shock but also the tolerance response 
to secondary LPS stimulation.  
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Figure 34. Kaplan Meier survival plots of Zeb1 (+/+) and Zeb1 (+/-) mice treated with a sub-lethal dose of 
LPS followed a lethal one (tolerance). 
 
 
 
 
Next, I sought to investigate whether the response of Zeb1 (+/-) mice to endotoxin shock 
or tolerance translated in a differential pattern of cytokine expression. Peritoneal 
macrophages from Zeb1 (+/+) and Zeb1 (+/-) mice were treated ex vivo with either a 
single dose or subsequent doses of LPS to mimic in vivo settings. Macrophages were 
then assessed for their expression of Tnfa (encoding TNFa) and Il10, the prototypical 
pro-inflammatory and anti-inflammatory cytokines responsible for the septic shock and 
tolerance, respectively (Sanchez-Tilló et al., 2007; Biswas and Lopez-Collazo, 2009). In 
line with in vivo results of Figure 33 and 34, I found that Zeb1 (+/-) macrophages 
expressed lower levels of Tnfa in response to septic shock and had lower expression of 
Il10 in response to tolerance (Figure 35).  
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Figure 35. Peritoneal macrophages from Zeb1 (+/+) and Zeb1 (+/-) mice were treated with either a single 
doses or subsequent doses of LPS. Expression of Tnf and Il10 were determined by qRT-PCR. 
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Chapter III :  Role of Zeb1 in the tumor 
microenvironment 
 
 
 
 
1. Zeb1 is upregulated in TAMs increasing SPMs and a 
pro-tumor profile 
 
 
My results above show that Zeb1 (+/-) macrophages display lower levels of SPM-
associated markers that are known to be also expressed by TAMs. Consequently, I first 
examined whether Zeb1 expression in peritoneal macrophages was modulated by the 
presence malignant cells. To that effect, I used again the ID8 ovarian carcinoma model.  
 
 
In wild-type mice, I found that Zeb1 expression was much higher in peritoneal TAMs 
obtained from mice that had been injected with ID8 cells during 13 weeks than in basal 
peritoneal macrophages mice that had never been exposed to tumor cells (Figure 36). 
Similar upregulation of Zeb1 was observed in peritoneal TAMs vis-à-vis normal 
peritoneal macrophages in Zeb1 (+/-) mice (Figure 36). Importantly, these results 
indicate that Zeb1 expression is activated by the presence of cancer cells and support a 
role for Zeb1 in the regulation of a TAM phenotype.  
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Figure 36.  Zeb1 expression increases during activation of peritoneal macrophages into TAMs. Zeb1 
mRNA levels were determined by qRT-PCR in peritoneal macrophages from Zeb1 (+/+) and Zeb1 (+/-) 
mice either under homeostasis conditions (peritoneal macrophages) or 13 weeks after injection of ID8 
carcinoma cells (peritoneal TAMs).  
 
 
 
 
 
I next explored whether or not expression of Zeb1 by macrophages affects their 
activation towards TAMs. Zeb1 (+/+) and Zeb1 (+/-) mice were injected with ID8 cells 
during 8 weeks and the resulting peritoneal TAMs were examined for the expression of 
genes associated with a TAM phenotype. I found that expression of Ccr2, Nfkb1/p50, 
Il1b, Il10, Cd163, Mrc1, Mmp9, and Vegf was significantly lower in peritoneal Zeb1 (+/-
) TAMs than in their wild-type counterparts (Figure 37). Interestingly, the archetypal M1 
Nos2 and M2 Arg1 genes—that displayed similar levels in both genotypes under 
homeostasis—were upregulated and downregulated, respectively, in Zeb1 (+/-) TAMs 
(Figure 37). The above data indicate that Zeb1 promotes the in vivo 
differentiation/activation of macrophages into TAMs, a process that is compromised in 
Zeb1 (+/-) mice. 
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Figure 37. Zeb1 (+/+) and Zeb1 (+/-) mice were injected with ID8 cells and 6 weeks later peritoneal TAMs 
were isolated and assessed for gene expression by qRT-PCR.  
 
 
 
 
In the ID8 ovarian cancer model, peritoneal TAMs with low expression of F4/80 
(F4/80low) (SPM-TAMs) display a strong pro-inflammatory and pro-angiogenic 
phenotype (e.g., high levels of Vegf, Il1b, Il6) that promotes ID8 cell proliferation 
(Hagemann et al., 2006; Cain et al., 2013; Rei et al., 2013). We examined the F4/80low 
(SPM-TAMs) and F4/80high (LPM-TAMs) subpopulations in the peritoneal exudate of 
Zeb1 (+/+) and Zeb1 (+/-) mice that had been injected with ID8 carcinoma cells for 6 
weeks. I found that, compared to wild-type mice, the F4/80high LPM-TAM subpopulation 
was expanded in Zeb1 (+/-) mice (Figure 38). Likewise, the ratio F4/80high to F4/80low in 
Zeb1 (+/-) TAMs was also higher than in Zeb1 (+/+) TAMs (Figures 38 and 39). Of note, 
this ratio was even higher in TAMs than in the normal macrophages shown in Figures 7 
and 8. The lower share of F4/80low in Zeb1 (+/-) TAMs reflects a deficient recruitment of 
circulating monocytes into the tumor microenvironment in Zeb1 (+/-) mice, which 
parallels the lower Ccr2 expression in Zeb1 (+/-) macrophages and TAMs (Figures 13 
and 37).  
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Figure 38. Left panels: Zeb1 (+/+) and Zeb1 (+/-) mice were injected with ID8 cells and the distribution of 
ID8 tumor (CD45-) and immune (CD45+) cells in peritoneal exudates was examined 6 weeks post-
inoculation. Right panels: CD45+ cells were then analyzed for CD11b and F4/80 expression to determine 
the distribution of SPM (F4/80low) and LPM (F4/80high) TAM subpopulations. On the left panels, gates 
represent total leukocytes (1) and ID8 tumor cells (2). On the right panels, gates represent SPMs (3) and 
LPMs (4) from gate (1).  
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Figure 39. As in Figure 38, expression of F4/80 was assessed in TAMs from Zeb1 (+/+) and Zeb1 (+/-) 
mice 6 weeks upon injection with ID8 carcinoma cells.  
 
 
 
 
The above results indicate that Zeb1 upregulates Ccr2 expression in macrophages and 
TAMs. I therefore investigated whether ZEB1 regulates Ccr2 by direct binding to its 
promoter. ZEB1 binds to a subset of E-box and E-box-like sequences in the regulatory 
regions of its target genes (Brabletz and Brabletz, 2010).  
 
 
Examination of the first 2 kb of the mouse Ccr2 promoter revealed the existence of at six 
ZEB1 high-affinity binding sequences (Figure 40). The ability of endogenous Zeb1 to 
directly bind to the Ccr2 promoter was tested for two of these sites (-868 bp and -818 bp) 
by chromatin immunoprecipitation (ChIP) assay in BMDMs from wild-type mice. It was 
found that an antibody against Zeb1, but not its respective host matched control IgG, 
immunoprecipitated a region of the mouse Ccr2 promoter containing both of these sites 
but not a region lacking consensus binding sites for Zeb1 (Figure 40).  
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Figure 40. ZEB1 binds to the mouse Ccr2 promoter. Upper panel: Scheme of 2 kb of the Ccr2 promoter. 
Consensus binding sites for ZEB1 in the first -2 kb of the Ccr2 promoter include six high affinity 
sequences (red boxes) at -1713 bp (CAGCTG), -1398 bp (CACCTG), -1136 bp (CAGCTG), -984 bp 
(CACGTA), -868 bp (CAGGTG), and -818 bp (CAGGTG). The regions examined by ChIP assay are 
represented by blue bars (see below). Lower panel: DNA from BMDM immunoprecipitated with 
antibodies against ZEB1 (E-20X) or goat IgG serum control was amplified by qRT-PCR for two regions of 
the Ccr2 promoter, one containing a consensus ZEB1 binding sites at – 868 bp and -818 bp (-868/-772 bp) 
and another lacking consensus binding sites for ZEB1 (non-binding site, NBS, -574/-422 bp) (blue bars in 
the upper panel). A condition without antibody is also shown. For each promoter fragment, the condition 
without antibody was equaled to 100.  
 
 
 
 
 
 
2. Expression of Zeb1 in F4/80low TAMs promotes tumor 
progression  
 
 
Within TAMs, those with F4/80low (SPM-TAMs), have a stronger pro-tumor effect by 
supporting cancer cell survival and tumor angiogenesis (Ostuni et al., 2015; Rei et al., 
2014). I therefore explored whether the smaller fraction of F4/80low SPM-TAM in Zeb1 
(+/-) mice affects tumor progression.  
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Zeb1 (+/+) and Zeb1 (+/-) mice were injected with ID8 cells and sacrificed 6 weeks later 
to examine tumor growth. I found that the number of ID8 cells in the peritoneal exudate 
of Zeb1 (+/-) mice—assessed as the percentage of CD45- cells—was drastically lower 
than in Zeb1 (+/+) mice (Left panel Figure 38 and Figure 41). These results indicate that 
Zeb1 expression in TAMs promotes tumor growth. I then investigated whether the more 
differentiated phenotype of ID8 cells when they have been injected in Zeb1 (+/-) mice 
than in Zeb1 (+/+) mice translated into a less aggressive tumor behavior. Indeed, 
compared to wild-type mice, there were not only lower number of ID8 cells in Zeb1 (+/-) 
mice, but I also detected fewer tumor deposits in the peritoneal lining of these mice 
(Figure 42).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41.  Reduced tumor growth of ID8 cells in Zeb1 (+/-) mice. As in the the percentage of ID8 cells in 
the peritoneal cavity of Zeb1 (+/+) and Zeb1 (+/-) mice was assessed by FACS 6 weeks after injection.  
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Figure 42. Representative images of the peritoneal lining of Zeb1 (+/+) and Zeb1 (+/-) mice 13 weeks after 
i.p. injection with ID8 carcinoma cells are shown.  
 
 
 
Also tumor progression of the ID8 tumor model in Zeb1 (+/+) and Zeb1 (+/-) mice was 
also followed over time by bioluminescence imaging. Mice from both genotypes were 
injected with ID8 cells that carried the luciferase-2 gene (ID8-luc) followed by 
administration of the cycLuc1 luciferase substrate. As shown in Figures 43 and 44, tumor 
load was lower in Zeb1 (+/-) mice than in Zeb1 (+/+) counterparts, confirming once again 
a faster tumor progression in a wild-type microenvironment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43. A Zeb1 (+/-) background suppresses tumor growth. Zeb1 (+/+) and Zeb1 (+/-) mice were 
injected with ID8-luc cells and tumor load progression was followed up over time by bioluminescence 
imaging. Tumor load in Zeb1 (+/+) was significantly larger than in Zeb1 (+/-) with a p ≤ 0.05 (*) at the 
indicated time points. Five mice of each genotype were included. 
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Figure 44. Representative pictures of the bioluminescence signal of mice for each genotype at week 6. 
 
 
 
Next, I investigated whether the smaller proportion of F4/80low TAMs in Zeb1 (+/-) mice 
alters the phenotype of the injected ID8 tumor cells. The expression of an epithelial 
phenotype in carcinomas, including E-cadherin, is associated with a less aggressive 
behavior (Perl et al., 1998; Sawada et al., 2008; and reviewed in Nieto et al., 2016). Mice 
from both genotypes were injected with ID8 cells and after 13 weeks they were sacrificed 
and ID8 cells were examined for the expression of a panel of genes, namely: Zeb1 itself, 
whose expression determines worse prognosis in most cancers; E-cadherin (Cdh1) and 
vimentin (Vim), the archetypal epithelial and mesenchymal markers, respectively (Nieto 
et al., 2016); Aldh1a1 and Kit, two cancer stem cell markers whose expression is 
associated with tumor progression and poorer prognosis in most carcinomas, including 
ovarian (Ginestier et al., 2007; Silva et al., 2011; Chau et al. 2013); and Mdr1/Abcb1, an 
efflux drug transporter whose expression is associated to chemotherapy resistance 
(Gottesman et al., 2002).  
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Interestingly, I found that expression of Zeb1 was higher in the ID8 cells isolated from 
peritoneal cavity of Zeb1 (+/+) mice than in those from Zeb1 (+/-) mice (Figure 45). In 
that line, expression of Vim, Aldh1a1, Kit and Mdr1 were also higher in ID8 cells 
recovered from Zeb1 (+/+) mice while Cdh1 was lower (Figure 45). Two conclusions can 
be raised from the above results: first, Zeb1 (+/+) TAMs elicit a greater tumor response 
than Zeb1 (+/-) counterparts, and second, Zeb1 expression in TAMs alters the functional 
phenotype of malignant cells triggering a mesenchymal, stem-like EMT phenotype and 
chemotherapy resistance. 
 
   
 
 
 
Figure 45. ID8 cells were either cultured in vitro (DMEM) or injected i.p. during 13 weeks into Zeb1 (+/+) 
and Zeb1 (+/-) mice. ID8 cells for the three conditions were assessed by qRT-PCR for the expression of the 
indicated genes in reference to Gapdh.  
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TAM infiltration associates with higher tumor cell resistance to chemotherapy (De Palma 
and Lewis, 2013). Therefore, I examined whether expression of Zeb1 in TAMs affected 
the response of ID8 cells to cisplatin. I found that ID8 cells isolated from Zeb1 (+/-) mice 
displayed higher sensitivity to cisplatin than ID8 isolated from wild-type counterparts 
(Figure 46). Likewise, incubation of ID8 cells with CM from wild-type TAMs, but not 
with CM from Zeb1-deficient TAMs, rendered cancer cells more resistant to cisplatin 
(Fig. 47). I can thus conclude that for TAMs to enhance resistance to cisplatin they have 
to express full levels of Zeb1. 
 
 
 
 
                                      
 
 
Figure 46. ID8 cells isolated from mice of both genotypes 8 weeks after injection were culture in complete 
medium or in the presence of 50 µg/ml of cisplatin and their viability assessed by an MTT assay.  
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Figure 47. ID8 cells were cultured in complete medium or treated with 50 µg/ml of cisplatin and then 
either incubated with CM from Zeb1 (+/+) or Zeb1 (+/-) TAMs.  
 
 
 
 
 
 
 
3.  Zeb1 activates a Ccr2-Mmp9-Ccl2 loop between TAMs 
and cancer cells 
 
Growth of ID8 cancer cells in the peritoneal cavity of a mouse activates the Src/Akt/Erk 
pathways and confers them with enhanced tumor aggressiveness (Cai et al. 2015). Thus, 
when ID8 cells are isolated from a mouse ascites and are reinjected into a new recipient 
mouse, these new ID8 cells—renamed hereafter as ID8RI—accelerate the onset and 
progression of tumor growth and ascites formation further (Cai et al., 2015). This 
indicates that the tumor microenvironment provided by the mouse peritoneal cavity 
modulates the functional phenotype of ID8 cells previously grown in vitro. I next tested 
the expression of Zeb1 and Ccl2 in ID8RI cells and found that, ID8RI cells that had 
grown in the peritoneal cavity of mice expressed higher levels of both genes than ID8 
cells (Figure 48).  
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Figure 48. ID8RI cells express higher levels of Zeb1 and Ccl2 than parental ID8 cells. ID8 and ID8RI cells 
were assessed for gene expression by qRT-PCR with respect to Gapdh.  
 
 
 
I next explored whether this higher expression of Ccl2 by ID8RI cells was modulated 
specifically by the expression of Zeb1 in TAMs. Since I found that ID8 cells that had 
been injected into Zeb1 (+/+) during 13 weeks expressed higher levels of Ccl2 than those 
that were injected in Zeb1 (+/-) mice (Figure 49 left panel). In fact, the ID8 cells that 
were injected in Zeb1 (+/-) mice display similar expression of Ccl2 than were not 
injected in mice and rather maintained in DMEM medium. I therefore cultivated ID8 
cells with conditioned medium (CM) collected from either normal peritoneal 
macrophages or TAMs from both genotypes. I found that Ccl2 expression was higher in 
ID8 cells incubated with CM from Zeb1 (+/+) macrophages or TAMs than in ID8 cells 
cultured with CM from Zeb1 (+/-) counterparts (Figure 49, center and right panels, 
respectively). Importantly, these results indicate that Zeb1 not only upregulates Ccr2 in 
TAMs (Figure 37) but also induces the expression of Ccl2 in cancer cells (Figure 49). By 
triggering this positive Ccr2-Ccl2 loop between TAMs and cancer cells, Zeb1 regulates 
the crosstalk between tumors and their microenvironment that contributes to tumor 
progression.  
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Figure 49. The expression of Ccl2 was examined by qRT-PCR in ID8 cells cultured in vitro in complete 
medium (DMEM), from 13 weeks tumor-bearing mice or co-cultured with conditioned medium (CM) from 
either Zeb1 (+/+) and Zeb1 (+/-) peritoneal macrophages (central panel) or with CM from Zeb1 (+/+) and 
Zeb1 (+/-) peritoneal TAMs (right panel).  
 
 
 
Production of the metalloproteinase MMP9 by tissue macrophages and TAMs is not only 
required for their migration and infiltration but it also promotes invasiveness and 
metastasis of malignant cells and tumor angiogenesis (Hiratsuka et al., 2002; Giraudo et 
al., 2004; Gong et al., 2008). I therefore explored whether the lower Mmp9 expression I 
observed in Zeb1-deficient macrophages and TAMs (Figures 13 and 37) participates in 
the more differentiated phenotype of ID8 cancer cells when injected in Zeb1 (+/+). I first 
examined whether the MMP9 produced by TAMs affected Ccl2 expression in ID8 cells. 
ID8 cells were incubated with CM from Zeb1 (+/+) and Zeb1 (+/-) TAMs in the presence 
of absence of an MMP9 allosteric inhibitor. Upregulation of Ccl2 in ID8 cells by CM 
from Zeb1 (+/+) TAMs was reduced by the MMP9 inhibitor (Figure 50). In contrast, 
Ccl2 expression was not altered by CM from Zeb1 (+/-) TAMs nor by the MMP9 
inhibitor (Figure 50). 
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Figure 50. ID8 cells were incubated with CM from Zeb1 (+/+) and Zeb1 (+/-) TAMs in the presence of 
absence of an MMP9 as described in Materials and Methods.   
 
 
 
 
 
This positive regulation of Ccl2 in ID8 cells by MMP9 was corroborated with 
recombinant mouse MMP9 (Figure 51) in ID8 cells and mouse recombinant CCL2 in 
peritoneal macrophages (Figure 52). Altogether these results indicate that lower MMP9 
production by Zeb1 (+/-) TAMs contributes, at least in part, to the lower induction of 
Ccl2 found in tumor cells that had grown in a Zeb1-deficient microenvironment. CCL2 
promotes tumor progression mainly by its effects on macrophages but CCL2 also has 
direct effects on tumor cells where it enhances cancer cell survival and motility, in part 
through the induction of MMP9 (Dagouassat et al., 2010; Fang et al., 2012).  
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Figures 51. Recombinant mouse MMP9 (rmMMP9) upregulated Ccl2 in ID8-luc cells. Data show three 
independent experiments. 
 
 
 
                                              
 
Figures 52. Recombinant mouse CCL2 (rmCCL2) induces MMP9 in peritoneal macrophages. Data show 
three independent experiments. 
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Blockade of CCL2-CCR2 signaling in macrophages reduces tumor progression and 
metastasis (Qian et al., 2011). I next tested the effect of blocking CCL2-CCR2 signaling 
on the phenotype of ID8 cells. ID8 tumor-bearing Zeb1 (+/-) and Zeb1 (+/+) mice were 
injected with a CCR2 small molecule antagonist and the CM produced by their 
respective TAM was use to culture ID8 cells in vitro. In line with the experiments above, 
the CM collected from Zeb1 (+/+) mice elicited higher Ccl2 expression in ID8 cells that 
the CM from Zeb1 (+/-) mice (Figure 49). Notably, the effect on Ccl2 expression by the 
CM from Zeb1 (+/+) mice was drastically inhibited by the CCR2 antagonist while it had 
no significant effect on ID8 cells that were cultured with Zeb1 (+/-) TAMs CM (Figure 
53).   
 
 
 
 
 
 
 
                                   
 
 
 
 
 
 
 
     
   
Figure 53. Blocking of CCL2-CCR2 signaling in TAMs inhibited Ccl2 expression in cancer cells. Wild-
type and Zeb1-deficient ID8 tumor-bearing mice were injected with a CCR2 antagonist and the CM 
produced by their respective TAM was added to ID8-luc cells and their expression of Ccl2 assessed by 
qRT-PCR as described in Methods. 
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4. More aggressive phenotype by tumor cells elicits a 
more pro-tumoral phenotype in TAMs 
 
 
My results above showed the progression of the ID8 cancer model and the phenotype of 
ID8 cancer cells are determined by the levels of Zeb1 expression in TAMs. Compared to 
wild-type TAMs, Zeb1-deficient TAMs, which also express lower levels of Mmp9 and 
Ccr2, trigger a more differentiated and less aggressive phenotype in ID8 cells. Since 
tumor cells also modulate the phenotype of TAMs, I examined whether a more or less 
aggressive phenotype of ID8 cells elicits a different TAM response. ID8 carcinoma cells 
were injected into Zeb1 (+/+) and Zeb1 (+/-) mice. After 13 weeks, tumor cells were 
isolated (ID8RI cells) and reinjected into wild-type mice during 6 weeks (see scheme of 
the experiment on top of Figure 54).  
 
 
I isolated TAMs in both experimental conditions and characterized their gene expression 
profile. It was found that the ID8RI cells obtained from wild-type mice—that 
consequently express higher levels of Ccl2 (Figure 48)—produced a stronger 
macrophage activation toward TAMs than the ID8RI cells isolated from Zeb1 (+/-) mice 
(Figure 54). Thus, the expression of Ccr2, Il1b, Il10, Cd163, Mrc1 and Mmp9 were 
higher in the TAMs isolated from wild-type mice injected with ID8RI previously grown 
in a wild-type tumor microenvironment that in the TAMs of also wild-type mice but 
injected with ID8RI previously grown in a Zeb1-deficient background. These results 
indicate that, independently of the recipient background—all recipient mice were wild-
type—the more aggressive and less differentiated ID8RI cells from wild-type have a 
greater capacity to induce macrophage activation towards TAMs than ID8RI cells that 
have been previously modulated by Zeb1-deficient TAMs. 
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Figure 54. ID8 cells that had been previously inoculated in Zeb1 (+/+) or Zeb1 (+/-) mice for 13 weeks 
(ID8-RI-wt and ID8-RI-het cells, respectively) were reinjected into Zeb1 (+/+) mice. After 6 weeks, TAMs 
were isolated and analyzed for their gene expression profile analyzed by qRT-PCR with reference to 
Gapdh.  
 
 
In line with the higher aggressiveness of ID8RI cells compared to ID8 cells, I found that 
after 6 weeks ID8RI isolated from wild-type mice cells developed similar levels of tumor 
deposits and ascites after only 6 weeks than those observed upon 13 weeks with parental 
ID8 cells. Interestingly, the ID8RI cells isolated from Zeb1 (+/-) mice resulted in lower 
ascites and tumor deposits than those rendered by ID8RI obtained from Zeb1 (+/+) mice  
(Figures 55). These results indicate that the slower tumor progression of ID8 cells in the 
context of Zeb1-deficient mice is transferable into wild-type mice. 
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Figures 55. Representative images of Zeb1 (+/+) mice injected with ID8 RI (+/+) and ID8RI  (+/-) 
showing ascites and tumor deposits in peritoneal cavity. 
 
 
 
 
5. Adoptive transfer of Zeb1-deficient macrophages into 
mice failed to promote tumor progression 
 
 
Previous figures have shown for the first time the importance of Zeb1-deficient or wild-
type microenvironment in tumor progression. Next, I sought to confirm that the reduced 
and delayed tumor progression of ID8 cells in Zeb1 (+/-) mice is due to the deficient pro-
tumor function of Zeb1 (+/-) macrophages. It has been reported that adoptive transfer of 
wild-type macrophages into tumor-bearing mice accelerates tumor progression 
(Hagemann et al., 2008).  
 
 
 
B
ID8RI from (+/+) mice into Zeb1 (+/+) mice 
ID8RI from (+/-) mice into Zeb1 (+/+) mice 
ID8 from (+/+) mice 
into Zeb1 (+/+) mice 
ID8 from (+/-) mice 
into Zeb1 (+/+) mice 
Zeb1 (+/+)
Zeb1 (+/-)
Zeb1 (+/+)
ID8
ID8
Zeb1 (+/+)
ID8
from 
(+/+)
ID8
from 
(+/-)
13 wks 6 wks
	 109	
I injected ID8RI cells into wild-type mice that were then divided in three cohorts. 
Twenty-three days later, one of the cohorts of tumor-bearing mice was injected i.p. with 
PBS while the other two cohorts were injected i.p. with BMDM derived from either Zeb1 
(+/+) and Zeb1 (+/-) mice [BMDMs (+/+) and BMDMs (+/-), respectively]. Tumor 
progression was then followed by luminescence bioimaging up to thirty days from the 
time of ID8RI cell injection. In line with Hagemann et al. (2008), tumor-bearing mice 
injected with BMDMs (+/+) displayed an accelerated tumor growth compared to those 
injected with PBS (Figure 56). Importantly, tumor-bearing mice injected with BMDMs 
(+/-) displayed a slower tumor progression than those injected with BMDMs (+/+) 
(Figure 56). These results indicate that expression of Zeb1 in macrophages (BMDM) and 
TAMs promotes tumor progression and that Zeb1-deficient TAMs are responsible for the 
reduced tumor progression of the ID8 carcinoma model in Zeb1 (+/-) mice.   
 
 
 
 Figure 56. ID8-luc cells isolated from Zeb1 (+/+) mice 13 weeks upon inoculation (ID8RI-wt) were 
reinjected in Zeb1 (+/+) mice that were then divided in three cohorts. At day 23, each cohort was 
inoculated i.p. with PBS, BMDM from Zeb1 (+/+) or BMDM from Zeb1 (+/-) mice. Tumor load 
progression was followed by bioluminescence and mice were euthanized seven days later.  
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After all mice were euthanized at day 30, ID8RI cells from the three cohorts were 
assessed for Ccl2 expression. ID8RI cells in the cohort that received BMDMs (+/+) 
expressed higher levels of Ccl2 than ID8RI cells isolated from mice injected with 
BMDMs (+/-) (Figure 57). These results further reinforce my results shown above 
indicating that Zeb1-deficient macrophages are unable to induce Ccl2 in tumor cells. 
 
                                        
 
Figure 57. Zeb1 (+/+) macrophages induce higher expression of Ccl2 in tumor cells than Zeb1 (+/-) 
macrophages. ID8-RI-wt isolated from the experiment in panel were assessed for Ccl2 expression by qRT-
PCR.  
 
 
 
 
6. TAM infiltration in human ovarian carcinomas correlates 
with higher ZEB1 tumor expression 
 
 
ZEB1 determines worse prognosis in a wide range of human cancers (Brabletz and 
Brabletz, 2010). Likewise, high expression of CCL2 in tumors correlates with poorer 
survival in most human cancers including ovarian carcinoma (Qian et al., 2011; Ostuni et 
al, 2015). Using survival data for 395 ovarian cancer patients, it was found that patients 
displaying high expression of both ZEB1 and CCL2 (red line in Figure 58) had lower 
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yellow lines in Figure 58). Patients with low expression of both ZEB1 and CCL2 
displayed the best survival probability. In other words, the maximum effect of ZEB1 as a 
predictor of reduced survival requires high levels of CCL2. This suggests that, at least for 
some of its tumor-promoting functions, ZEB1 depends on CCL2 expression. 
 
   
 
            
 
 
 
 
 
 
 
 
 
 
 
 
Figure 58. Ovarian cancer patients with the highest expression of ZEB1 and CCL2 (red line) have shorter 
progression-free survival than those with high expression of ZEB1 but low expression of CCL2 (green line) 
or high CCL2 but low ZEB1 (yellow line) or that display low levels of both genes (blue line). Their 
survival probability was plotted in a Kaplan Meier graph according to a best cut off expression as detailed 
in Supplementary Information.  
 
 
 
In most human epithelial tissues, ZEB1 is not expressed in the normal epithelium 
although it is found in stromal cells. However, ZEB1 greatly increases in most human 
carcinomas, including epithelial ovarian carcinomas (Jin et al, 2014). To corroborate my 
results using the ID8 carcinoma mouse model, I investigated ZEB1 expression in TAMs 
and its association to TAM-associated markers in human epithelial ovarian cancer. To 
that effect, a series of serous ovarian carcinomas was stained for ZEB1, CCL2, CD163, 
CCR2 and MMP9 (Figures 59, 60 and 61). It was found that infiltration of the tumor 
microenvironment by TAMs correlated with higher expression of ZEB1 by tumor cells. 
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Higher expression of ZEB1 by these TAMs also associated with their higher expression 
of CCR2 and MMP9. Lastly, expression of ZEB1 in tumor cells associated with that of 
CCL2. These results further support previous results in this study showing that ZEB1 is 
expressed in both TAMs and tumor cells and that ZEB1 expression in TAMs induces the 
expression of TAM-associated markers.  
 
 
 
  
 
     
Figure 59. Expression of ZEB1 (HPA027524), CCL2 (2D8), CD163 (10D6), CCR2 (48607), and MMP9 
(E11) in human serous ovarian carcinomas. Representative pictures of the tumor and its microenvironment 
are shown. Magnification 400X. 
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Figure 60. Quantification of data from Figure 55. The percentage of tumor cells and TAMs expressing 
each protein was determined and cases were then segregated by their expression of ZEB1—in tumor cells 
or in TAMs—below or above the median into two cohorts (Low ZEB1 and High ZEB1). The means for 
CCL2 expression in tumor cells (n = 18), the percentage of TAM infiltration—determined by expression of 
CD163—(n = 18), and the expression of CCR2 (n = 15) and MMP9 (n =15) in TAMs was calculated for 
the low and high ZEB1 cohorts and the significance of their difference was assessed by a Mann-Whitney U 
test. 
 
 
 
                                     
 
Figure 61. Correlations between relevant protein expression pairs in tumor cells and/or TAMs in serious 
ovarian carcinomas (n = 15) were assessed by a Spearman’s correlation coefficient (r). Their significance is 
represented by the p value.   
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In the ID8 mouse model I found that expression of Zeb1 by TAMs promoted tumor 
progression. Therefore, I studied whether ZEB1 expression in TAMs affected the 
prognosis of ovarian carcinoma patients. Importantly, I found that higher expression of 
ZEB1 in TAMs was associated with poorer survival in these patients (Figure 62). 
                  
 
 
 
Figure 62 High expression of ZEB1 in TAMs in human serous ovarian carcinomas determined poorer 
overall survival. Expression of ZEB1 (clone HPA027524) in TAMs (CD163, clone 10D6) was assessed by 
immunostaining. 
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This project has used different technical approaches to determinate the role of Zeb1 in 
macrophages both during homeostasis and in the tumor microenvironment. The results 
shown in this dissertation indicate that ZEB1 regulates the response to inflammatory 
challenge and tolerance and have also defined a pro-tumoral role of Zeb1 in the tumor 
microenvironment beyond its already known expression in tumor cells. 
 
 
Although ZEB1 has a role in the differentiation of many cellular types, including 
hematopoietic cells (Vandewalle et al., 2009; Goosens and Haigh, 2012), its expression 
and function in myeloid differentiation has not been studied. In this study I showed that 
ZEB1 is expressed in myeloid cells and has an essential role in both their differentiation 
and activation. Interestingly, during myeloid maturation, monocytes have higher levels of 
Zeb1 than macrophages. In turn, SPMs express more Zeb1 than LPMs that are almost 
negative for Zeb1. In that line, in Zeb1-deficient mice the LPM subpopulation and total 
macrophage count are higher than in normal wild-type mice. Different levels of Zeb1 
expression resulted in distinct status of activation and polarization since Zeb1 
heterozygous macrophages have lower levels of expression of both anti and pro-
inflammatory cytokines (Okabe et al., 2014). 	
 
 
Comparison of the RNAseq data from wild-type and Zeb1-deficient macrophages 
confirmed their different polarization/activation pattern as well as provided evidence for 
the role of ZEB1 in a number of other immune and non-immune functions. 
Downregulation of Zeb1 levels in macrophages resulted in the differential expression of 
over 400 genes, associated to 150 GO pathways. This wealth of information obtained 
from the RNAseq analysis will also open new areas of research on the role of ZEB1 in 
macrophages.   
 
 
Zeb1 regulated and was regulated by Socs3, an important gene in macrophage regulation. 
Zeb1 was not regulated by or regulate Socs2, since Socs2 (-/-) and Socs2 (-/-) Zeb1 (+/-) 
mice had a similar peritoneal macrophage distribution and gene profile. However, the 
results with Socs3 mice showed a potential regulation of Zeb1 by Socs3 as Socs3Lyz2cre 
macrophages expressed less Zeb1 than Zeb1 (+/-) animals. Overall, the phenotype of 
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Socs3Lyz2cre/Zeb1 (+/-) mice was similar to that of Zeb1 (+/-) mice but, if anything, even 
more pronounced. Thus, peritoneal macrophage distribution in these mice showed a large 
difference between SPM and LPM subpopulations and a similar genetic expression 
profile. My results indicated that some genes are directly modulated by one of them 
whereas others, (as the classical Socs3 targets Il6) depended on both genes showing 
differential expression in the presence or lack of each or in their mutual expression. 
Despite its structural and functional homology with Socs3, there was not regulatory or 
functional relationship between Zeb1 and Socs2. 
 
 
Zeb1 also had a role in the phagocytic activity of peritoneal macrophages. Macrophage 
polarization modulates the capacity of macrophages to in phagocytosis with M1 
macrophages being more efficient than M2 macrophages (Martinez and Gordon, 2014). 
LPMs are responsible for the phagocytosis of apoptotic cells and tissue repair assuming a 
role in the maintenance of physiological conditions, while SPMs are responsible for 
controlling infections and inflammatory process. I have showed that LPMs represent a 
larger share in Zeb1 (+/-) mice and showed less M2-related gene profile than in wild-type 
mice and, likewise, Zeb1-deficient macrophage presented a higher phagocytic capability 
than wild-type macrophages. ZEB1 impaired the clearance of malignant cells, but it 
remains to be studied whether it also enhances macrophage phagocytic capacity of 
pathogens as well apoptotic cells. For instance, macrophages deficient for Vim, a gene 
activated by Zeb1, are more efficient in the phagocytosis of bacteria, which results in 
lower inflammatory response in acute colitis model (Mor-Vaknin et al., 2013). 
 
 
Among the genes differentially expressed between both wild-type and Zeb1-deficient 
macrophages was Ccr2. Blocking CCL2-CCR2 signaling inhibited the ability of TAMs 
to upregulate Ccl2 in cancer cells. In that line, I found that Zeb1-deficient macrophages 
had impaired migration rate upon CCL2 stimulus. The reduced migration of Zeb1-
defiecient macrophages could be related to the fact that LPM macrophages are tissue-
resident macrophages, and they have a role controlling tissue homeostasis whereas SPMs 
are more similar to dendritic cells with respect to inflammation and antigen presentation 
and, consequently, they migrate faster than LPMs. 
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Nevertheless, even in the absence of chemotactic stimuli, Zeb1 deficient macrophages 
also displayed lower migratory ability than wild-type macrophages, and the mechanism 
that modulates this basal motility capacity will be explored in the future. Thus, the 
RNAseq showed a number of motility-related genes downregulated in Zeb1-deficient 
macrophages, such as those involved in actin polymerization and cellular contractility, 
and via enhanced ECM degradation and invasion. It is worth noting that ZEB1 regulates 
motility and prometastatic invasion in tumor cells, through actin cytoskeletal remodeling 
by downregulating miR-34a expression (Ahn et al., 2012). Taken together these data 
indicate that as ZEB1 modulates motility and migration in tumor cells, in macrophages 
would have a similar role regulating their normal migratory capacities.  
 
 
The role of ZEB1 in the migration of macrophages was also corroborated in vivo. In vivo 
migration is influenced by the composition of the local extracellular matrix (ECM) but 
my in vivo model showed that the regulation of Zeb1 regulating migration is intrinsic to 
macrophages themselves, independent of the mouse background. Certain MMPs may be 
involved both positively and negatively in monocyte/macrophage migration. Even 
double Mmp2 (-/-) Mmp9 (-/-) monocytes showed reduced infiltration, suggestive of a 
reduction in migration (Agrawal et al., 2006). Likewise, knockdown of three MMP7, 
MMP9 and MMP18 demonstrated that they are necessary for normal macrophage 
migration in vivo (Tomlinson et al., 2008). It could be therefore postulated that reduced 
levels of MMP9 in Zeb1 (+/-) macrophages contribute to their lower migratory capacity.  
 
 
In macrophages, CSF1 functions as both a growth factor and an important regulator of 
macrophage motility (Pixley, 2012). An in vivo differentiation model in response to 
CSF1 showed the role of ZEB1 both in monocyte migration as along their differentiation 
to mature macrophages. In this model, I found that Zeb1 is blocking LPM subpopulation 
maturation, this based on the observation of decreased LPM in wild-type mice exposed 
to CSF1. As discussed earlier, endogenous cytokines modulate myeloid cells attraction, 
but exogenous bacterial products such as LPS can also mobilize monocytes at the 
inflammatory focus. In fact, I found that monocyte mobilization to peritoneal cavity 
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could be mediated by CSF1 or CCL2, and also by tumor cells stimulus, probably for 
exogenous chemokines that are generated for cancer cells.  
 
 
Interestingly, Zeb1-deficient bone marrow cells displayed improved capacity to 
differentiate and reconstitute the LPM population compared to wild-type bone marrow 
cells, in a wild-type animal background where Zeb1 deficiency in injected myeloid cells 
is the only variable. Furthermore, these results together with the higher Zeb1 in monocyte 
population, suggest that Zeb1 might have a role in maintaining stemness in hematopoietic 
progenitor cells and support the hypothesis that Zeb1 is blocking the maturation of 
myeloid progenitor cells into a mature macrophage lineage. Also this is supported by the 
fact that ZEB1 can modulate stemness features in tumor cells (Wellner et al., 2009). 
These data are also consistent with other studies showing that Ccr2 is downregulated 
during myeloid maturation, being therefore a marker of immature monocytes. Similarly 
Zeb1 would be acting probably modulating Ccr2 expression and thus macrophage 
migration and maturation.  
 
 
A number of transcription factors participate in the differentiation of progenitor cells into 
monocytes and then into mature macrophages. Of note, and some of these factors are 
regulated by ZEB1 (e.g., Pu.1, c-Myc and c-myb) (Lawrence and Natoli, 2011; Lavin et 
al., 2014). My results here set Zeb1 as a new member of the transcription factors 
implicated in hematopoietic differentiation. Notably, Zeb2 regulates plasmocytoid 
dendritic cell lineage, and in Zeb2-deficient mice there is differentiation impairment in 
myeloid cells (Li et al., 2016, Wu et al., 2016). Hence it is possible to speculate that Zeb1 
has a similar role in myeloid lineage wherein blocking terminal differentiation in 
macrophages.  
 
 
 
In that line, our group is generating Zeb1 and Zeb2 floxed mice that will be crossed with 
LyzM-Cre mice in order to obtain the specific deletion of Zeb1 and Zeb2 in macrophages. 
These mice will prove very useful to study to explore whether specific deletion of Zeb1 
in macrophages not only alters the phenotype of TAMs, vis-à-vis TAMs in Zeb1 (+/-) 
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mice but also how this influences the progression of the ID8 cancer model. I expect a 
slower progression of the ID8 model in Zeb1f/fLisMCre than wild-type mice. Likewise, my 
hypothesis is that progression of the ID8 model in the Zeb2f/fLisMCre would accelerate it 
since they would have not the myeloid terminal differentiation and would has more 
TAM-like immature myeloid cells. 
 
 
Zeb1 deficiency protected mice from death upon a single dose of LPS (toxic shock), 
which correlates with the decreased expression of pro or anti-inflammatory genes in their 
macrophages. Of note, SPM and LPM subpopulations have different responses to LPS in 
vivo. Thus, SPMs produce increased amounts of inflammatory cytokines (i.e. TNFα and 
RANTES), and LPMs migrate to omentum and decreased in number in peritoneal cavity 
(Okabe et al., 2014; Rei et al., 2015) and SPM/LPM ratio is altered by Zeb1 levels.  
Hence, Zeb1 (+/-) mice with lesser SPM subset display decreased expression of 
inflammatory cytokines and improve their survival.  
 
 
Interestingly, Zeb1-deficient macrophages failed to acquire a tolerance state and failed to 
survive. During tolerance, macrophages undergo a reduction in pro-inflammatory 
cytokines and adopt a reparative and wound healing polarization profile. In order to 
understand my in vivo results and how Zeb1 is regulating this process, I examined the 
gene expression profile in both models for in wild-type and Zeb1-deficient mice. Tnfα 
one of the most important pro-inflammatory genes involved in mortality of septic shock 
was significantly upregulated in wild-type macrophages, but not in Zeb1-deficient 
macrophages. Moreover, the same occurs with the Il10 gene in tolerance model that was 
upregulated in wild-type macrophages but not in Zeb1-deficient counterparts and the 
inability of the latter to control inflammation, help explaining the death of Zeb1 (+/-) 
mice died in the tolerance model. 
 
 
LPS in monocytes modulates active histone marks at promoter and enhancers of genes in 
the lipid metabolism and phagocytic pathways.  Furthermore, histone deacetylases 
(HDACs) are involved in macrophage differentiation, metabolism, and activation 
(Alvarez-Errico et al., 2014; Lloberas et al., 2016; Novakovic et al., 2016). ZEB1 is a 
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transcription factor, which in turn can recruit (HDACs), in T cells ZEB1 together with 
CtBP-2 and HDAC1 repress the IL2 promoter (Wang et al., 2009). 
 
 
 It remains to elucidate whether similar regulation takes place in macrophages through 
HDAC and whether Zeb1 can modulate macrophage functions referred above. Indeed, 
the expression of “non tolerizable” genes as Il10 depends of the maintenance of 
H3K4me3 mark of acetylation at different of “tolerizable” genes in front to second 
inflammatory stimulus (Alvarez-Errico et al., 2014). This information together the fact 
H3K4me3 regulates transcriptional activation of ZEB1 (Chaffer et al., 2013) indicates 
that ZEB1 is implicated in the control of inflammation in macrophages. 
 
 
ZEB1 expression in cancer cells promotes tumor initiation and progression. I show here 
that, ZEB1 is also induced in TAMs at the TME where it plays a parallel tumor-
promoting function than in cancer cells although through a different mechanism. ZEB1 
in TAMs activates a Ccr2-Mmp9-Ccl2 feedback loop between tumor cells and TAMs, 
and induces a more aggressive phenotype in cancer cells (see model in Figure 63).  
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Figure 63. Expression of Zeb1 in TAMs induces tumor progression by activation of a Ccr2-Mmp9-Ccl2 
loop between TAMs and cancer cells. 
 
 
Of note, this tumor-promoting loop was inhibited by just a partial downregulation of 
Zeb1 in TAMs. Compared to wild-type TAMs, reduced expression of Mmp9 in Zeb1 (+/-
) TAMs results in lower levels of expression of Ccl2 in tumor cells. Of note, it was found 
that a more aggressive phenotype by tumor cells—with higher Ccl2 and Zeb1 
expression— elicits a more pro-tumoral phenotype in TAMs, including higher levels of 
Ccr2 and Mmp9. Importantly, injection of wild-type macrophages, but not Zeb1-deficient 
ones, into wild-type tumor-bearing mice accelerated tumor growth and upregulated Ccl2 
expression in tumor cells. In human ovarian carcinomas, TAM infiltration in the 
microenvironment correlated with ZEB1 expression by cancer cells and higher ZEB1 
expression in TAMs associated with higher levels of CCR2 and MMP9. Altogether, my 
results indicate that, ZEB1 plays an important role in the crosstalk between tumor cells 
and their microenvironment and that ZEB1 expression in TAMs enhances pro-tumor 
phenotype in cancer cells and promotes tumor growth. 
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F4/80low SPM-TAMs express a pro-tumor and pro-angiogenic phenotype and, compared 
to F4/80high LPM-TAMs, stimulate enhanced tumor growth (Rei et al., 2014). This 
dissertation found that Zeb1 is not only restricted to F4/80low SPM normal macrophages 
and TAMs but that it also expands this subpopulation. Deletion of Zeb1 downregulated 
the expression of an SPM-associated gene profile in normal macrophages and TAMs and 
reduced the F4/80low SPM-TAM population. These effects help explaining the slower 
progression of tumors in Zeb1 (+/-) mice and the failure of Zeb1-deficient macrophages 
to accelerate tumor growth compared to PBS when injected in tumor-bearing mice.  
  
 
Although the expression of ZEB1 among stromal cells of the tumor microenvironment 
has been noted, the identity of the cell types expressing ZEB1 (e.g., fibroblast, 
macrophages, other immune cells) had not been until now established (Spaderna et al., 
2006; Chaffer et al., 2013; Isella et al., 2015). In that line, this is the first study to 
characterize the expression and function of ZEB1 in the tumor microenvironment. Zeb1 
expression in macrophages was drastically upregulated when macrophages were exposed 
to cancer cells. I also showed that the activation of normal macrophages toward a pro-
tumoral F4/80low SPM TAMs is compromised in Zeb1-deficient mice and that the 
expression of pro-tumor and pro-angiogenic genes in TAMs was downregulated. 
Furthermore, I showed that cancer cells also modulate the phenotype of TAMs—ID8RI 
cells isolated from tumor-bearing wild-type mice trigger a stronger pro-tumoral 
phenotype in TAMs than ID8RI cells obtained from Zeb1-deficient mice. 
   
 
Importantly, this study shows that, like in tumor cells, Zeb1 expression in TAMs 
triggered in vitro and in vivo a more dedifferentiated and aggressive phenotype in 
adjacent malignant cells. Thus, Zeb1 in TAMs upregulates genes associated with a 
mesenchymal and stem-like phenotype and to resistance to chemotherapy in tumor cells, 
including expression of Zeb1 itself. Loss of epithelial markers (e.g., Cdh1) and 
acquisition of an EMT phenotype (e.g., Vim, Zeb1) by epithelial cells is required for 
adenoma-to-carcinoma transition and increased aggressiveness in epithelial tumors (Perl 
et al., 1998; Liu et al., 2014). In turn, cancer cells induce Zeb1 in peritoneal macrophages 
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and TAMs. The role of ZEB1 promoting tumor progression is therefore supported by a 
positive feedback of its expression between malignant cells and TAMs. Tumor 
infiltration by TAMs promotes tumor growth, angiogenesis and metastasis (Franklin and 
Li, 2016) and I found that a partial downregulation of Zeb1 in TAMs was sufficient to 
hinder TAM pro-tumor functions and to drastically reduce tumor growth in the ID8 
cancer model. Notably, this deficient pro-tumor function of Zeb1 (+/-) TAMs was 
transferable into wild-type tumor-bearing mice. Of note, c-myc, a proto-oncogene that 
promotes cancer cell proliferation, is also expressed by TAMs although its function in 
TAMs (e.g., tumor promoting or suppressing) has not been studied (Pello et al., 2012; 
Valledor et al., 2008).  
  
 
Expression of ZEB1 by malignant cells is a well-established prognostic and predictive 
biomarker in most cancers (Brabletz and Brabletz, 2010). My results here has shown that 
downregulation of ZEB1 in TAMs decreases their pro-tumor functions thus setting ZEB1 
expression in stromal cells in the microenvironment as a relevant target in cancer 
therapy. All these data presented here, introduced a new role of ZEB1 in myeloid lineage 
opening new possibilities to modulate ZEB1 expression in the innate immune system in 
the context of chronic inflammation, autoimmune disorders and cancer disease. The dual 
role of ZEB1 promoting tumor progression in cancer cells and TAMs—and through 
different mechanisms—has important implications for strategies aimed at blocking 
ZEB1. The simultaneous and mutually reinforcing expression of ZEB1 in TAMs and 
tumor cells sets ZEB1 as a target in cancer therapy whose expression has to be 
modulated at multiple levels. Emerging new diagnostic approaches in ovarian cancer 
patients like liquid biopsies would allow to evaluate ZEB1 levels in peritoneal 
macrophages in order to determine personalized treatment, prognosis, staging, and 
response to treatment. 
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• Zeb1 inhibits the differentiation of myeloid precursors towards LPMs and activates 
F4/80low-associated genes. 
 
 
• Zeb1 reduces macrophage phagocytic capacity while increasing their migration towards 
inflammatory foci and the tumor microenvironment. 
 
 
• Zeb1 expression in macrophages increases in the context of cancer cells where it 
reprograms TAMs towards a pro-tumoral phenotype. 
 
 
• Zeb1 in TAMs promotes a dedifferentiated and chemotherapy-resistant phenotype in 
cancer cells and promotes tumor progression in vivo by activating a Ccr2-Mmp9-Ccl2 
loop between TAMs and cancer cells.  
 
 
• In ovarian carcinomas, ZEB1 expression in tumor cells correlates with higher infiltration 
of TAMs and expression of ZEB1 in both cancer cells and TAMs determines poorer 
survival. 
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